

ROBERT J. DiDOMENICO, JR.

CURRICULUM VITAE

PERSONAL DATA

University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Practice (M/C 886)
833 South Wood Street
Chicago, Illinois 60612
Phone: (312) 996-1342
Fax: (312) 996-0379
Email: rddom1@uic.edu
Website: <https://pharmacy.uic.edu/people-resources/directory/rddom1>

LICENSURE Registered Pharmacist, Illinois, Lic. No. 051-040893

PROFESSIONAL EXPERIENCE

1997 – 1999 **Pharmacotherapist, Amiodarone/Electrophysiology Clinic**
University of Illinois Medical Center at Chicago Heart Center

1997 – 1999 **Specialist in Poison Information**
Illinois Poison Control Center
Metropolitan Chicago Healthcare Council
Rush-Presbyterian-St. Lukes Medical Center

1998 – 1999 **Clinical Pharmacist, Cardiology Clinic**
Veterans Administration Chicago Healthcare System
West Side Division

1999 – present **Cardiovascular Clinical Pharmacist**
University of Illinois Hospital & Health Sciences System
Department of Hospital Pharmacy Services

ACADEMIC APPOINTMENTS

University of Illinois at Chicago

1996 – 1999 **Clinical Associate**
College of Pharmacy
Department of Pharmacy Practice

1999 – 2006 **Clinical Assistant Professor**
College of Pharmacy
Department of Pharmacy Practice

2003 – 2008 **Team Leader, Critical Care Pharmacotherapy**
University of Illinois Medical Center at Chicago
Department of Hospital Pharmacy Services
College of Pharmacy
Department of Pharmacy Practice

2003 – present **Center Affiliate**
Center for Pharmacoepidemiology and Pharmacoeconomic Research (CPR)
College of Pharmacy

2004 – 2005 **Clinical Assistant Professor**

	College of Medicine Section of Cardiology
2006 – 2015	Clinical Associate Professor College of Pharmacy Department of Pharmacy Practice
2007 – 2017	Curricular Team Leader College of Pharmacy Classes: 2010, 2013, 2014 – 2017 (3 rd professional year)
2015 – 2017	Clinical Professor College of Pharmacy Department of Pharmacy Practice
	<i>Percent effort</i>
	Patient care and Clinical Teaching 46%
	Public and Professional Service 28%
	Administration 8%
	Research and Scholarship 7%
	Didactic teaching 6%
	Mentoring 5%
2017 – present	Associate Professor with tenure College of Pharmacy Department of Pharmacy Practice
	<i>Percent effort</i>
	Research and Scholarship 25%
	Patient care and Clinical Teaching 25%
	Public and Professional Service 25%
	Administration 10%
	Didactic teaching 10%
	Mentoring 5%

POST-DOCTORAL TRAINING

1996 – 1997	Pharmacy Practice Residency Director: Linda R. Bressler, Pharm.D. University of Illinois at Chicago College of Pharmacy
1997 – 1999	Cardiovascular Pharmacotherapy Fellowship Director: Jerry L. Bauman, Pharm.D., BCPS, FCCP, FACC University of Illinois at Chicago College of Pharmacy

EDUCATION

1989 – 1992	Pre-Pharmacy Studies University of Illinois at Chicago
1992 – 1996	Doctor of Pharmacy (with Honors) University of Illinois at Chicago College of Pharmacy

CERTIFICATION

1996 – present	CPR Healthcare Provider. American Heart Association.
1996 – present	Acute Cardiac Life Support Provider. American Heart Association.
2015 – present	Added Qualifications in Cardiology (AQ Cardiology). Board of Pharmaceutical Specialties.

2015 – present [Board Certified Pharmacotherapy Specialist \(BCPS\)](#). Board of
Pharmaceutical Specialties

HONORS AND AWARDS

1997 Richard A. Hutchinson Award for Excellence in Pharmacy Practice
1998 ACCP 1998 Spring Practice and Research Forum Best Student, Resident, Fellow
Paper Award Competition Finalist
1999 Academic Employee of the Month, University of Illinois Hospital
1999 Marion Merrell Dow Fellowship Research Award
2001 Inducted into Rho Chi Society, Phi Chapter
2002 Class Act Award, Employee Recognition Committee, University of Illinois
Hospital
2005 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,
Pharmacy Practice Residency
2005 PharmD of the Year Nominee; University of Illinois at Chicago, College of
Medicine Housestaff Physicians
2005 Teacher of the Year Honorable Mention; University of Illinois at Chicago, College
of Pharmacy, Class of 2007
2006 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,
Class of 2006
2006 PharmD of the Year Nominee; University of Illinois at Chicago, College of
Medicine Housestaff Physicians
2007 12th ISPOR Annual International Meeting Contributed Research Award for Best
Poster Presentation
2007 PharmD of the Year Nominee; University of Illinois at Chicago, College of
Medicine Housestaff Physicians
2008 American College of Clinical Pharmacy (ACCP) Research Institute Investigator
Development Award
2008 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,
Pharmacy Practice (PGY1) Residency
2008 Golden Apple Award Nominee; University of Illinois at Chicago, College of
Pharmacy, Class of 2008
2008 Preceptor of the Year Nominee; University of Illinois at Chicago, College of
Pharmacy, Class of 2008
2012 Inducted into *Phi Lambda Sigma* Pharmacy Leadership Society, *Alpha Iota*
chapter
2013 Fellow, American College of Clinical Pharmacy (FCCP)
2017 Fellow, American College of Cardiology (FACC)
2017 Fellow, Heart Failure Society of America (FHFA)

LEADERSHIP ACTIVITIES

Organizational

American College of Clinical Pharmacy (ACCP) Practice-Based Research Network (PBRN)

2016 – 2017 Vice-Chair, Community Advisory Panel (CAP)
2017 – 2018 Chair, Community Advisory Panel (CAP)

American College of Clinical Pharmacy (ACCP) Cardiology Practice and Research Network (PRN)

2002, 2008 Chair-Elect Candidate
2010 – 2012 Co-Chair, Awards and Recognition Committee
2014 – 2015 Chair, Research and Scholarship Committee

2015 – 2016	Chair-Elect
2015 – 2016	Vice-Chair, Programming Committee
2016 – 2017	Chair
2016 – 2017	Chair, Programming Committee
2017 – 2018	Chair, Nominations Committee

University of Illinois Hospital & Health Sciences Center

2008 – 2010	Co-Chair, Cardiovascular (CV) Quality Improvement (QI) Committee
2009 – 2010	Chair, CVQI Committee, 30-day Readmissions Subcommittee
2016 – 2017	Chair, PATient Navigator to rEduce Readmissions (PARTNER) Publications Committee

University of Illinois at Chicago College of Pharmacy

2005 – 2006	Chair, EPC Pharmacokinetics Working Group
2008 – 2018	Chair, Educational Policy Committee (EPC) Significant achievements under my leadership include incorporation of lecture capture technology into the classroom, expansion to a distance campus (Rockford, IL; 2010), ACPE re-accreditation (2014-5), revised professional curriculum (2015), implementation of revised curriculum (2016-2018)
2013 – 2014	Co-Chair, American Council for Pharmaceutical Education (ACPE) Self-Study Committee, Curriculum Subcommittee
2014 – 2015	Chair, Curriculum Revision Phase III-Curriculum Development

University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice

2005	Chair, Strategic Planning Committee, Workload Subcommittee
2005	Chair, Strategic Planning Committee, Curriculum Revision Subcommittee
2007	Chair, Drug Information Group Director Search Committee
2018 – present	Chair, Promotion and Tenure Committee
2019 – present	Interim Assistant Head

Pharmaceutical Industry

2005	Co-Chair, Scios, Inc. Regional Pharmacy Advisory Board; Chicago, Illinois
------	---

Community

2017 – 2018	Lead, Residential Promotion. St. Alphonsus/St. Patrick School Celtic Fund Marketing Committee. Lemont, Illinois.
-------------	--

PUBLICATIONS

(Corresponding author underlined)

Scholarly Works in Progress

1. Goncharenko A, Groo VL, Mansour I, Gans C, Stamos T, **DiDomenico RJ**. Trends in medication optimization during hospitalization for acute decompensated heart failure. *J Card Fail* [In preparation].
2. **DiDomenico RJ**, Ng T, Benge CD, Hale G, Nappi J, Pickworth K, Campbell KB, Buckley L, Macaulay TE, Short, M, Ripley TL. Comparison of PGY2 cardiology pharmacy residency learning experiences. *Am J Health-Syst Pharm* [In preparation].
3. Patel H, Calip GS, **DiDomenico RJ**, Schumock G, Suda K, Lee TA. Prevalence of cardiac risk factors in patients using azithromycin before and after the FDA warning. [In preparation].

4. Landup D, Bress AP, **DiDomenico RJ**. Chapter 5: Ischemic heart disease. In: Katz M, Matthias K, Chisholm-Burns MA, eds. *Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach, 5th edition*. Chicago: McGraw-Hill. [In preparation].
5. Hellenbart EL, Dwyer SM, **DiDomenico RJ**. Chapter 7: Principles of heart failure pharmacotherapy. In Butler J, Skopicki H, Murali S, Kalogeropoulos A, eds. *Heart Failure: An Essential Clinical Guide*. New York: Taylor & Francis. [in preparation].
6. **DiDomenico RJ**, Dobesh PP, Finks SW. Chapter 33: Acute coronary syndromes. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, eds. *Pharmacotherapy: A Pathophysiologic Approach, 11th ed*. New York: McGraw-Hill Education. [Submitted].
7. Ng T, **DiDomenico RJ**, Ripley TL, Benghe CD, Buckley L, Campbell KB, Hale G, Macaulay TE, Nappi J, Pickworth K, Short, M,. An opinion paper of the American College of Clinical Pharmacy Cardiology Practice and Research Network outlining recommendations for training of cardiovascular pharmacy specialists in post-graduate year 2 residency programs. *JACCP* [Submitted].
8. Basu S, Bracken N, Dickens C, **DiDomenico RJ**, Gallardo R, Gordeuk V, Hsu L, Illendula S, Joo M, Mutso A, Pickard AS, Pittendrigh B, Prieto-Centurion V, Williams M, Krishnan JA. Design of the Patient Navigator to Reduce Readmissions (PARTNER) study: a pragmatic clinical effectiveness trial. *Contemp Clin Trials Commun* [Submitted].
9. Kim K, Ardati A, Cavallari L, Touchette DR, **DiDomenico RJ**. Cost-effectiveness of genotype/phenotype driven ticagrelor versus clopidogrel selection in patients with acute coronary syndrome. *Cardiovasc Drug Ther* [Submitted].

Primary Literature

1. **DiDomenico RJ**, Chami YG, Bauman JL. Unstable Angina Pectoris Associated with Phentermine in a Patient with Known Coronary Artery Disease. *J Appl Ther Res* 1998;2:63-7.
2. **DiDomenico, RJ**. New antithrombotics for the ICU setting: GP IIb/IIIa inhibitors, low-molecular-weight heparins, and direct thrombin inhibitors. *Crit Care Nurs Q* 2000;22(4):61-74. [PMID: 11852966](#). Invited review.
3. **DiDomenico RJ**, Sanoski CA, Walton SM, Bauman JL. Analysis of the use of digoxin immune Fab for the treatment of non-life-threatening digoxin toxicity. *J Cardiovasc Pharmacol Therapeut* 2000;5(2):77-85. [PMID: 11150387](#)
4. Schoen MD, **DiDomenico RJ**, Connor SE, Bauman JL. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. *Pharmacotherapy* 2001;21:1455-63. [PMID: 11765297](#)
5. **DiDomenico RJ**. Reimbursement mechanisms for glycoprotein IIb/IIIa-receptor inhibitors. *Am J Health-Syst Pharm* 2002;59(Suppl 7):S37-42. Invited review. [PMID: 12434713](#)
6. Galanter WL, **DiDomenico RJ**, Polikaitis A. Preventing exacerbation of an ADE with automated decision support. *J Healthc Inf Manag* 2002;16:44-9. [PMID: 12365299](#)
7. Bauman JL, **DiDomenico RJ**. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. *J Cardiovasc Pharmacol Therapeut* 2002;7:195-202. [PMID: 12232568](#). Invited review.
8. **DiDomenico RJ**, Eyrich HM. Did contrast nephropathy in RAPPID really occur? *J Am Coll Cardiol* 2003;42:2167. [letter]. [PMID: 14680745](#)
9. Eckhoff C, **DiDomenico RJ**, Shapiro NL. Initiating warfarin therapy: is 5mg or 10mg superior? *Ann Pharmacother* 2004;38:2115-21. Epub 2004 Nov. 2. [PMID: 15522981](#)
10. Galanter WL, Polikaitis A, **DiDomenico RJ**. A trial of automated safety alerts for inpatient digoxin use with computerized physician order entry. *J Am Med Inform Assoc* 2004;11:270-7. Epub 2004 Apr 2. [PMID: 15064288](#)

11. **DiDomenico RJ**, Park H, Southworth MR, Eyrich HM, Lewis RK, Finley JM, Schumock GT. Guidelines for acute decompensated heart failure treatment. *Ann Pharmacother* 2004;38:649-60. Epub 2004 Feb 24. ACPE Program # 407-000-04-015-H01. [PMID: 14982975](#)
12. **DiDomenico RJ**. Randomized trial of warfarin nomograms. *Ann Intern Med* 2004;140:489-90. [letter]. [PMID: 15023723](#)
13. **DiDomenico RJ**, Massad MG, Kpodonu J, Navarro RA, Geha A. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. *Chest* 2005;127:1828-35. [PMID: 15888865](#)
14. Galanter WL, **DiDomenico RJ**, Polikaitis A. A trial of automated decision support alerts for contraindicated medications using computerized physician order entry. *J Am Med Inform Assoc* 2005;12:269-74. Epub 2005 Jan. 31. [PMID: 15684124](#)
15. **DiDomenico RJ**, Massad MG. Pharmacologic strategies to prevent atrial fibrillation after open-heart surgery. *Ann Thorac Surg* 2005;79:728-40. [PMID: 15680883](#)
16. Desai SS, Massad MG, **DiDomenico RJ**, Abdelhady K, Hanhan Z, Lele H, Snow NJ, Geha AS. Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? *Rec Patents Cardiovasc Drug Disc* 2006;1:307-16. [PMID: 18221095](#)
17. Bauman JL, **DiDomenico RJ**, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. *Arch Intern Med* 2006;166:2539-45. [PMID: 17159022](#)
18. Bauman JL, **DiDomenico RJ**, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. *Am J Cardiovasc Drugs* 2006;6:77-86. [PMID: 16555861](#). Invited review.
19. Vats V, **DiDomenico RJ**, Wojtynek J, Theobald J, Schumock GT. Hospital policies for treatment of acute decompensated heart failure. *Ann Pharmacother* 2007;41:562-7. Epub 2007 Mar. 20. [PMID: 17374618](#)
20. **DiDomenico RJ**, Perez A, Eyrich HM, Fontana DR, Kondos GT, Schumock GT. Impact of treatment guidelines on clinical and economic outcomes of acute decompensated heart failure. *Ann Pharmacother* 2008;42:327-33. Epub 2008 Feb. 26. [doi: 10.1345/APH.1k496](#).
21. **DiDomenico RJ**, Kondos GT, Dickens C. Recent national trends in readmission rates after heart failure hospitalization. *Circ Heart Fail* 2010;3:e13.[letter]. doi: [10.1161/CIRCHEARTFAILURE.110.947614](#).
22. Chow SL, Singh H, **DiDomenico RJ**, Dunn SP, Johnson SG, Marrs JC, Vardeny O, Bleske BE. Key articles related to complementary and alternative medicine in cardiovascular disease: Part 2. *Pharmacotherapy* 2011;31:208e-277e. [doi: 10.1592/phco.31.10.1041](#).
23. Perez A, Touchette DR, **DiDomenico RJ**, Stamos TD, Walton SM. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. *Pharmacotherapy* 2011;31:552-65. [doi: 10.1592/phco.31.6.552](#).
24. Yu S, Galanter WL, **DiDomenico RJ**, Borkowsky S, Schiff GD, Lambert BL. Selection of drug-laboratory result pairs for an inpatient asynchronous alert program: results of a Delphi survey. *Am J Health-Syst Pharm* 2011;68:407-14. [doi: 10.2146/ajhp100215](#).
25. Milfred-Laforest SK, Chow SL, **DiDomenico RJ**, Dracup K, Ensor C, Gattis-Stough W, Heywood JT, Lindenfeld J, Page II RL, Patterson JH, Vardeny O, Massie BM. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. *J Cardiac Fail* 2013;19:354-60. Epub 2013 Apr 6. [doi: 10.1016/j.cardfail.2013.02.002](#).
26. Milfred-Laforest SK, Chow SL, **DiDomenico RJ**, Dracup K, Ensor C, Gattis-Stough W, Heywood JT, Lindenfeld J, Page II RL, Patterson JH, Vardeny O, Massie BM. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. *Pharmacotherapy* 2013;33:529-48. Epub 2013 May 3. [doi: 10.1002/phar.1295](#).

27. Wiggins BS, Rodgers JE, **DiDomenico RJ**, Miller AE, Page RL. Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by the members of the American College of Clinical Pharmacy's Cardiology PRN based on the Hospital to Home (H2H) Initiative. *Pharmacotherapy* 2013;33:558-80. Epub 2013 Mar 25. doi: [10.1002/phar.1231](https://doi.org/10.1002/phar.1231).
28. Nutescu EA, Bathija S, Chan J, Engle J, Grim S, Mucksavage J, Ohler K, Shapiro NL, Tesoro E, **DiDomenico RJ**. Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty. *Pharmacotherapy* 2014;34:1239-49. Epub 2014 Dec 4. doi: [10.1002/phar.1521](https://doi.org/10.1002/phar.1521).
29. **DiDomenico RJ**, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL. Use of a Simplified Nomogram to Individualize Digoxin Dosing versus Standard Dosing in Patients with Heart Failure. *Pharmacotherapy* 2014;34:1121-31. Epub 2014 Aug 28. doi: [10.1002/phar.1480](https://doi.org/10.1002/phar.1480).
30. Dorsch MP, Lose J, **DiDomenico RJ**. The effect of cardiovascular credentialed pharmacists on process measures and outcomes in myocardial infarction and heart failure. *Pharmacotherapy* 2014;34:803-8. Epub 2014 Jun 5. doi: [10.1002/phar.1444](https://doi.org/10.1002/phar.1444).
31. Prieto-Centurion V, Markos MA, Ramey NI, Gussin H, Nyenhuis S, Joo MJ, Prasad, B, Bracken N, **DiDomenico R**, Godwin PO, Jaffe HA, Kalhan, R, Pickard AS, Pittendrigh B, Schatz B, Sullivan JL, Thomashow BM, Williams MV, Krishnan JA. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations: a systematic review. *Ann Am Thorac Soc* 2014;11:417-24. doi: [10.1513/Annals/ATS.201308-254OC](https://doi.org/10.1513/Annals/ATS.201308-254OC).
32. Lose J, Dorsch MP, **DiDomenico RJ**. Comparison of practice patterns between inpatient cardiology pharmacists with and without added qualifications in cardiology. *Hosp Pharm* 2015;50:51-8. doi: [10.1310/hjp5001-051](https://doi.org/10.1310/hjp5001-051).
33. Ursan ID, Krishnan JA, Pickard AS, Calhoun E, **DiDomenico R**, Prieto-Centurion V, Sullivan JL, Valentino L, Williams MV, Joo M. Engaging patients and caregivers to design transitional care management services at a minority serving institution. *J Health Care Poor Underserved* 2016;27:352-65. doi: [10.1353/hpu.2016.0026](https://doi.org/10.1353/hpu.2016.0026).
34. Hanigan S, **DiDomenico RJ**. Emerging therapies for acute and chronic heart failure: hope or hype? *J Pharm Pract* 2016;29:35-45. doi: [10.1177/1933719115615877](https://doi.org/10.1177/1933719115615877). Invited review.
35. **DiDomenico RJ**. Digoxin remains a viable option to control heart rate in patients with atrial fibrillation. *Can J Hosp Pharm* 2017;70:391-2. doi: <http://dx.doi.org/10.4212/cjhp.v70i5.1701>. Invited review.
36. Haines ST, Baker WL, **DiDomenico RJ**. Improving Peer Review: What Journals Can Do. *Am J Health-Syst Pharm* 2017;74:2086-9. Epub 2017 Oct 26. doi: [10.2146/ajhp170188](https://doi.org/10.2146/ajhp170188). Invited review.
37. **DiDomenico RJ**, Baker WL, Haines ST. Improving Peer Review: What Reviewers Can Do. *Am J Health-Syst Pharm* 2017;74:2080-4. Epub 2017 Oct 26. doi: [10.2146/ajhp170190](https://doi.org/10.2146/ajhp170190). Invited review.
38. Baker WL, **DiDomenico RJ**, Haines ST. Improving Peer Review: What Authors Can Do. *Am J Health-Syst Pharm* 2017;74:2076-9. Epub 2017 Oct 26. doi: [10.2146/ajhp170187](https://doi.org/10.2146/ajhp170187). Invited review.
39. Allender JE, Reed BN, Foster JL, Moretz JD, Oliphant CS, Jennings DL, **DiDomenico RJ**, Coons JC. Pharmacologic considerations in patients receiving left ventricular percutaneous mechanical circulatory support. *Pharmacotherapy* 2017;37:1272-83. Epub 2017 Jul 25. doi: [10.1002/phar.1995](https://doi.org/10.1002/phar.1995).
40. Kim K, Lee TA, Ardati AK, **DiDomenico RJ**, Touchette DR, Walton SM. Comparative effectiveness of oral antiplatelet agents in patients with acute coronary syndrome. *Pharmacotherapy* 2017;37:877-87. Epub 2017 May 27. doi: [10.1002/phar.1961](https://doi.org/10.1002/phar.1961)
41. Kim K, **DiDomenico RJ**, Touchette DR, Walton SM. Letter—The authors respond. *J Manag Care Spec Pharm* 2017;23:599-600. doi: [10.18553/jmcp.2017.23.5.599](https://doi.org/10.18553/jmcp.2017.23.5.599)
42. Kim K, Lee TA, Touchette DR, **DiDomenico RJ**, Ardati AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. *J Manag Care Spec Pharm* 2017;23:57-63. doi: [10.18553/jmcp.2017.23.1.57](https://doi.org/10.18553/jmcp.2017.23.1.57).

43. Kim, K, Lee TA, **DiDomenico RJ**, Ardati AK, Touchette DR, Walton SM. Comparison of six-month costs between oral antiplatelet agents following acute coronary syndrome. *J Manag Care Spec Pharm* 2018;24:800-12. doi: [10.18552/jmcp.2018.24.8.800](https://doi.org/10.18552/jmcp.2018.24.8.800).
44. **DiDomenico RJ**. Residency application deadlines: Can we all just agree on a date? *Am J Health-Syst Pharm* 2018;75:849-50. doi: [10.2146/ajhp170882](https://doi.org/10.2146/ajhp170882).
45. Zueger PM, Kumar VM, Harrington R, Rigoni G, Atwood AM, **DiDomenico RJ**, Touchette DR. Cost-effectiveness analysis of sacubitril-valsartan for the treatment of heart failure with reduced ejection fraction in the United States. *Pharmacotherapy* 2018;38:520-30. Epub 2018 Mar 30. doi: [10.1002/phar.2108](https://doi.org/10.1002/phar.2108).
46. **DiDomenico RJ**. Cardiology clinical pharmacy practice—keep spreading the news! *JACCP* 2018. Epub 2018 Oct 23. <https://doi.org/10.1002/jac5.1048>. Invited editorial.
47. Gasbarro NM, **DiDomenico RJ**. Frequency of “on-label” use of intravenous diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter. *Am J Health-Syst Pharm* 2019;76:214-20. <https://doi.org/10.1093/ajhp/zxy033>
48. Reed BN, **DiDomenico RJ**, Allender JE, Coons JC, Cox JF, Johnson D, Oliphant CS, Jennings DL. Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers. *J Interv Cardiol* 2019;3791307. <https://doi.org/10.1155/2019/3791307>

Book Chapters

1. **DiDomenico RJ**, Einhorn AE. Medical emergencies: cardiac arrest. In: Anderson PO, Knoblen JE, Troutman WG, eds. *Handbook of Clinical Drug Data*, 10th ed. Chicago: McGraw-Hill, 2002.
2. **DiDomenico RJ**. Cardiovascular drugs: inotropic drugs. In: Anderson PO, Knoblen JE, Troutman WG, eds. *Handbook of Clinical Drug Data*, 10th ed. Chicago: McGraw-Hill, 2002.
 - 11th edition, 2010.
3. **DiDomenico RJ**. Cardiovascular drugs: nitrates. In: Anderson PO, Knoblen JE, Troutman WG, eds. *Handbook of Clinical Drug Data*, 10th ed. Chicago: McGraw-Hill, 2002.
 - 11th edition, 2010.
4. **DiDomenico RJ**. Hematologic drugs: coagulants & anticoagulants. In: Anderson PO, Knoblen JE, Troutman WG, eds. *Handbook of Clinical Drug Data*, 10th ed. Chicago: McGraw-Hill, 2002.
5. **DiDomenico RJ**. Hematologic drugs: hematopoietics. In: Anderson PO, Knoblen JE, Troutman WG, eds. *Handbook of Clinical Drug Data*, 10th ed. Chicago: McGraw-Hill, 2002.
6. **DiDomenico RJ**, Mucksavage J. Anemia of critical illness: prevention and treatment. In: *Pharmacotherapy Self-Assessment Program, 5th ed; Book 11: Critical Care/Transplantation*. Kansas City: American College of Clinical Pharmacy, 2006.
7. Cavallari LH, **DiDomenico RJ**. Chapter 4: Ischemic heart disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, Dipiro JT, eds. *Pharmacotherapy Principles & Practice*. Chicago: McGraw-Hill, 2007. **Book received the American Medical Writers Association Distinguished 2008 Medical Book Healthcare Professionals Award.**
 - 2nd edition, 2010.
 - 3rd edition, 2013.
 - 4th edition (**DiDomenico RJ**, Cavallari LH), 2016. <https://ppp.mhmedical.com/content.aspx?bookid=1793§ionid=120648222>
 - 5th edition (Landup D, **DiDomenico RJ**), 2019. <https://ppp.mhmedical.com/content.aspx?bookid=2440§ionid=189491747>
8. Cavallari LH, **DiDomenico RJ**, Peska G. Chapter 5: Ischemic heart disease. In: Katz M, Matthias K, Chisholm-Burns MA, eds. *Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach*. Chicago: McGraw-Hill, 2010.
 - 3rd edition (Cavallari LH, **DiDomenico RJ**, Bress A), 2013.
 - 4th edition (Bress A, Cavallari LH, **DiDomenico RJ**), 2017.

9. **DiDomenico RJ**, Cavallari LH. Chapter 6: Chronic stable angina. In: Crouch MA, ed. *Cardiovascular Pharmacotherapy: A Point of Care Guide*. Bethesda: American Society of Health-System Pharmacists, 2010.
10. **DiDomenico RJ**. Chapter 6. Fibrinolytics. In: Wiggins B, Sanoski S, eds. *Emergency Cardiovascular Pharmacotherapy: A Point-of-Care Guide*. Bethesda: American Society of Health-System Pharmacists, 2012.
11. **DiDomenico RJ**, Page RL. Chapter 12: Digoxin. In Murphy J, ed. *Clinical Pharmacokinetics, 6th ed.* Bethesda: American Society of Health-System Pharmacists, 2017.
12. **Dobesh PP**, **DiDomenico RJ**, Rogers KC. Chapter 32: Stable ischemic heart disease. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, eds. *Pharmacotherapy: A Pathophysiologic Approach, 11th ed.* New York: McGraw-Hill Education, 2019.
<https://accesspharmacy.mhmedical.com/content.aspx?bookid=2577§ionid=211042403>

Miscellaneous Projects/Publications (Non-Peer Reviewed)

1. **DiDomenico RJ**, Seeger JD. Clinically relevant drug-drug interactions with warfarin (Coumadin[®]). UICMC Hospital Pharmacy Services and Drug Information Service; Chicago, Illinois. *Nursing-Rx News* 1997;3(6).
2. **DiDomenico RJ**. Continuing education: review of the glycoprotein IIb/IIIa inhibitors. *KeepPosted* 1998;23(9):6-16.
3. **DiDomenico RJ**, Schoen MD. Clinical case study: management of hypertension. *KeepPosted* 1998;23(5):6-12.
4. **DiDomenico RJ**. Ischemic heart disease. CPE Program: Pharmaceutical Care and Disease State Management in Community Pharmacy. June, 2000.
5. **DiDomenico RJ**. Therapeutic class review of thrombolytic agents for myocardial infarction. Novation/University Health-System Consortium. March, 2000.
6. **DiDomenico RJ**. Clinical use of fenoldopam, a selective dopamine agonist: potential application to the perioperative setting. *Anesthesia Today* 2002;13:19-26.
7. **DiDomenico RJ**. What's new...in the management of hypertension and dyslipidemia? Presented as part of a pharmacy distance learning program for Continuing Education credit (ACPE Universal Program #: 073-000-03-082-L01) entitled "A Review of Selected New Drugs During the Beginning of the Twenty-First Century sponsored by University of Wisconsin-Madison School of Pharmacy, Department of Extension Services in Pharmacy (ESP). September 23 – November 11, 2003.
8. Beitelshes AL, Humma, LM, **DiDomenico RJ**. Low-molecular-weight heparin vs unfractionated heparin in acute coronary syndromes: Which should be used in patients going to the cath lab? *Today in Cardiology* 2003;6(1):18.
9. **DiDomenico RJ**. Coronary artery disease. *Tech Topics™* July 2004;9(3):1-28. ACPE Program # 121-000-03-109-H01.
10. **DiDomenico RJ**. Drug therapy to prevent atrial fibrillation after open heart surgery in patients at risk. *Anesthesia Today* 2005;16:21-6.
11. Fontana D, **DiDomenico RJ**. Nesiritide: the latest drug for treating acutely decompensated congestive heart failure. Fremont: Scios, Inc., 2006.
12. **DiDomenico RJ**. Using critical pathways and pharmacoeconomics to guide ADHF treatment decisions. Continuing education credit: 0.2 CEU (ACPE Program #204-000-06-407-H01). Bethesda: ASHP Advantage, 2006.
13. **DiDomenico RJ**. Pharmacological management of AF. *Hospital Pharmacy Europe* 2006;May/June:1-2.

14. Crouch MA, **DiDomenico RJ**, Rodgers JE. Applying consensus guidelines in the management of acute decompensated heart failure. Continuing education credit: 0.2 CEU (ACPE Program #204-000-06-407-H01). Bethesda: ASHP Advantage, 2007.
15. Labinov Y, **DiDomenico R**. The role of platelet function monitoring during thienopyridine/P2Y₁₂ therapy. [Cardiology Today, March 2013](#).
16. Labinov Y, **DiDomenico R**, **Cavallari L**. Pharmacists' role in warfarin pharmacogenetics. *Keyposted* 2013;39:9-10.
17. Gasbarro N, **DiDomenico RJ**. The role of ivabradine in reducing the risk for cardiovascular mortality or hospitalization for worsening heart failure. *Pharmacy Practice News Special Report/Advertorial*. New York: McMahon Publishing. May, 2016.
18. DiDomenico R. Message from the chair: righting a wrong on board certification. *The Heart Beat: Cardiology Practice and Research Network (PRN) Newsletter*. Lanexa: American College of Clinical Pharmacy. July, 2017.
19. **Baker WL**, **DiDomenico RJ**. Heart failure: pumping up knowledge, circulating new approaches. *Drug Topics*; May 2017:54-64. Continuing education credit: 0.2 CEU (ACPE Program #0009-9999-17-008-H01-P, #0009-9999-17-008-H01-T).
20. DiDomenico R. Message from the chair. *Cardiology Practice and Research Network (PRN) Membership Information*. Lanexa: American College of Clinical Pharmacy. Spring, 2017.

SCIENTIFIC ABSTRACTS

(Presenting author italicized)

Published Abstracts

1. **DiDomenico RJ**, Sanoski CA, Walton SM, Bauman JL. Cost-Effectiveness Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity. *Pharmacotherapy* 1998;18:427[Abstract 8]. Poster presentation: American College of Clinical Pharmacy (ACCP) 1998 Spring Practice and Research Forum; Palm Springs, CA. April, 1998.
2. **DiDomenico RJ**, Schoen MD, Connor SE, Bauman JL. Impact of Cost of Prescription Drugs on Clinical Outcomes in Patients with Heart Disease. *Pharmacotherapy* 1999;19:506[Abstract 181]. Platform presentation: American College of Clinical Pharmacy (ACCP)/European Society of Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy; Orlando, FL. April, 1999.
3. **DiDomenico RJ**, Fain J, Bauman JL. Cost-Minimization Analysis of Early, Elective Cardioversion Guided by Transesophageal Echocardiography Followed by Early Hospital Discharge for the Acute Management of Atrial Fibrillation. *Pharmacotherapy* 2000;20:1229-1301 [Abstract 196]. Poster presentation: American College of Clinical Pharmacy (ACCP) Annual Meeting; Los Angeles, CA. November, 2000.
4. **Beitelshes A**, Southworth MR, Dunlap S, **DiDomenico RJ**, Humma L. Cost Savings Associated with a Decreased Need for Potassium Supplementation in Heart Failure Patients on Spironolactone. *Pharmacotherapy* 2002;22:1327[Abstract 20]. Platform presentation: American College of Clinical Pharmacy (ACCP) annual meeting; Albuquerque, NM. October, 2002.
5. **Galanter WL**, **DiDomenico RJ**, Polikaitis A. Analysis of Medication Safety Alerts for Inpatient Digoxin Use With Computerized Physician Order Entry. *J Gen Intern Med* 2002;17(suppl 1):193[Abstract Tracking ID #50281]. Poster presentation: Society of General Internal Medicine. Atlanta, GA. May, 2002.
6. **DiDomenico RJ**, Park H, Southworth MR, Eyrich HE, Lewis RK, Finley JM, Schumock GT. Development of Guidelines for the Treatment of Acute Decompensated Heart Failure. *Pharm World Sci* 2004;26:A113[Abstract PT-062]. Poster presentation: 2nd American College of Clinical Pharmacy (ACCP) – European Society of Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy; Paris, France. April, 2004.
7. **Schumock GT**, **DiDomenico RJ**, Blackburn J, Walton SM, Hilleman DE. Early Therapy with Nesiritide in Hospitalized Patients with Acute Decompensated Heart Failure Associated with Reduced Costs: a

- Markov Analysis. *Pharmacotherapy* 2005;25:1493[Abstract 273E]. Poster presentation: 2005 Annual American College of Clinical Pharmacy (ACCP) meeting; San Francisco, CA. October, 2005.
8. *Eyrich HM, DiDomenico RJ, Fontana DR, Kondos GT, Schumock GT.* Treatment Guidelines for Acute Decompensated Heart Failure Associated with Improved Outcomes. *Pharmacotherapy* 2005;25:1439[Abstract 33]. Platform presentation: 2005 Annual American College of Clinical Pharmacy (ACCP) meeting; San Francisco, CA. October, 2005.
 9. Blackburn J, **DiDomenico RJ**, Hilleman DE, Walton SM, Schumock GT. Early Therapy with Nesiritide in Hospitalized Patients with Acute Decompensated Heart Failure Associated with Reduced Costs: A Markov Analysis. *J Card Fail* 2005;11(suppl.):S178[Abstract 332]. Poster presentation: 9th Annual Heart Failure Society of America (HFSA) Scientific Meeting. Boca Raton, FL. September, 2005.
 10. **DiDomenico RJ**, Viana M, Fitch M, Bauman JL. A new and simple dosing algorithm for digoxin in patients with heart failure. *J Card Fail* 2006;12(suppl.):S85[Abstract 273]. Poster presentation: 10th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Seattle, WA. September, 2006.
 11. *Agusala P, Fontana D, DiDomenico R, Groo V, Stamos T, Vaitkus PT.* The effects of nesiritide and other vasoactive agents on renal function. *J Card Fail* 2006;12(suppl.):S88[Abstract 285]. Poster presentation: 10th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Seattle, WA. September, 2006.
 12. *Blackburn JC, DiDomenico R, Walton SM, Hilleman DE, Schumock GT.* Markov-based economic analysis of nesiritide in acute decompensated heart failure. *Value Health.* 2006;9(3):A124 [Abstract PCV20]. Poster presentation: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual Meeting. Philadelphia, PA. May, 2006.
 13. *Fontana D, Vuckovic K, DiDomenico RJ, Stamos TD.* Long-Term Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure Stratified by Baseline Renal Function and Blood Pressure. *Circulation* 2006;113:e804[Abstract P88]. Poster presentation: American Heart Association's 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. Washington, DC. May, 2006.
 14. *Fitch M, DiDomenico RJ, Viana M, Bauman JL.* Methods for dosing digoxin in heart failure in the modern era. *Pharmacotherapy* 2006;26:e41[Abstract 176]. Poster presentation: American College of Clinical Pharmacy (ACCP) 2006 Spring Practice and Research Forum (Runner Up, Best Student, Resident, Fellow Paper Award). Monterey, CA. April, 2006.
 15. *Perez A, DiDomenico R, Schumock GT, Theobald J, Wojtynek J.* Evaluation of acute decompensated heart failure management in membership hospitals of a group purchasing organization. *Pharmacotherapy* 2007;27[Abstract 330]. Poster presentation: 2007 Annual American College of Clinical Pharmacy (ACCP) meeting; Denver, CO. October, 2007.
 16. *Vats V, DiDomenico RJ, Wojtynek J, Theobald J, Schumock GT.* Hospital Policies for the Treatment of Acute Decompensated Heart Failure. *Value Health.* 2007;10:A53 [Abstract PCV58]. Poster presentation: 12th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Arlington, VA. May, 2007.
 17. **DiDomenico RJ, Sengupta N, Barker C.** Impact of Nesiritide on Treatment of Acute Decompensated Heart Failure (ADHF): Evidence from a US Hospital Database. *Value Health.* 2007;10:A47 [Abstract PCV35]. Poster presentation: 12th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Arlington, VA. May, 2007.
 18. *Sauve JM, Tokumar SM, DiDomenico RJ, Kao JA.* Clinical outcomes of patients on clopidogrel with a hemorrhagic episode. *Crit Care Med* 2006;34:A63[Abstract 238]. Poster presentation: 36th Annual Critical Care Congress of the Society of Critical Care Medicine. Orlando, FL. February, 2007.
 19. *Greenhalgh E, DiDomenico RJ.* Predictors of Diuretic Resistance in Patients with Acute Decompensated Heart Failure. *J Card Fail* 2008;14(Suppl 1):S80 [Abstract 257]. Poster presentation: 12th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Toronto, Ontario, Canada. September, 2008.

20. *Perez A, DiDomenico RJ, Theobald J, Wojtynek J, Schumock GT. Evaluation of the Effect of Acute Decompensated Heart Failure Guidelines in Community Hospitals. Value Health. 2008;11 [Abstract PCV82]. Poster presentation: 13th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Toronto, Ontario, Canada. May, 2008.*
21. *DiDomenico RJ, Schumann HM, Bauman JL. Digoxin Toxicity in the Modern Era. Clin Tox 2008;46:368[Abstract 66]. Poster presentation: 2008 European Association of Poison Centres and Clinical Toxicologists (EAPCCT) meeting; Seville, Spain. May, 2008.*
22. *Bautista A, Stein BD, Lee TA, Meltzer DO, DiDomenico RJ, Krishnan JA, Schumock GT. Specificity of Administrative Data for Identifying Heart Failure Patients for Hospital Quality Performance Initiatives. Value Health 2009;12:A161[Abstract PCV107]. Poster presentation: 14th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Orlando, FL. May, 2009.*
23. *Greenhalgh E, Groo V, Stamos TD, DiDomenico RJ. Torsemide vs Furosemide Plus Metolazone for Symptomatic Heart Failure. Pharmacotherapy 2009;29:e88[Abstract 198]. Poster presentation: 2009 American College of Clinical Pharmacy (ACCP)/European Society of Clinical Pharmacy International Congress on Clinical Pharmacy. Orlando, FL. April, 2009.*
24. *Groo VL, Williams K, Dickens C, Stamos TD, DiDomenico RJ. Evaluation of 30-day Heart Failure Readmissions. Pharmacotherapy 2010;30:431e[abstract 234]. Poster presentation: 2010 American College of Clinical Pharmacy (ACCP) Annual Meeting. Austin, TX. October, 2010.*
25. *DiDomenico RJ, Na-Thalang K, Tsao Y, Groo VL, Bishop JR, Viana MAG, Bauman JL. Use of a Simplified Nomogram to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care. Pharmacotherapy 2010;30:376e[abstract 39]. Platform presentation: 2010 American College of Clinical Pharmacy (ACCP) Annual Meeting. Austin, TX. October, 2010.*
26. *Schlemmer RF, Briars LA, DiDomenico RJ, Peverly SL, Rabi SM. Assessing Strategies to Encourage Student Completion of Course and Instructor Evaluations. Am J Pharm Educ 2010;74:Article 96(page 1)[Abstract]. Poster presentation: 2010 American Association of Colleges of Pharmacy Annual Meeting. Seattle, WA. July, 2010.*
27. *Musselman ME, Bursua AJ, DiDomenico RJ, Shroff A, Groo VL. Prescribing patterns of proton pump inhibitors in patients requiring clopidogrel post-drug eluting stent. Pharmacotherapy 2010;30:e180[Abstract 106]. Poster presentation: 2010 American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum. Charlotte, NC. April, 2010.*
28. *Bress A, Groo VL, DiDomenico RJ, Stamos TD, Patel S, Cavallari LH. The Effect of Epithelial Sodium Channel Genotype on Loop Diuretic Requirements in Systolic Heart Failure: the First 50 Subjects. Pharmacotherapy 2011;31:e415-6[Abstract 381]. Poster presentation: 2011 American College of Clinical Pharmacy (ACCP) Annual meeting. Pittsburgh, PA. October, 2011.*
29. *Nutescu E, Lee YM, Dotiwala Z, Stamos T, Nehmer M, Walrath K, DiDomenico R, Ruland S, Thambi M, Galanter W. Improving the quality of heparin anticoagulation to meet Joint Commission National Patient Safety Goals. J Thromb Thrombolysis 2011;31:372 [Abstract A10]. Poster presentation: Anticoagulation Forum's 11th National Conference on Anticoagulant Therapy. Boston, MA. May, 2011.*
30. *Nutescu EA, DiDomenico R, Bathija S, Grim S, Mucksavage J, Tesoro E, Ohler K, Thielke J, Chan J, Shapiro N, Engle J. Balance of academic responsibilities of clinical track pharmacy faculty in the US. Pharmacotherapy 2012;32:e190[Abstract 42]. 2012 American College of Clinical Pharmacy (ACCP) Annual meeting. Hollywood, FL. October, 2012.*
31. *Dickens C, Vuckovic K, Nehmer M, DiDomenico R, Kerbow D, Stamos T, Kondos G, Piano M. Improving the heart failure readmission rate at an urban medical center. West J Nurs Res 2012;34:1066-7. Epub 2012 Aug 6. PMID 22868988. Poster presentation: 36th Annual Midwest Nursing Research Society (MNRS) Doctor of Philosophy Student Poster Award (Honorable Mention). Dearborn, MI. April, 2012.*
32. *Dorsch MP, Lose J, DiDomenico RJ. The Effect Of Cardiovascular Credentialed Pharmacists On Process Measures and Outcomes In Myocardial Infarction and Heart Failure. Pharmacotherapy*

- 2013;33:e192.[Abstract 33E]. 2013 American College of Clinical Pharmacy (ACCP) Annual meeting. Albuquerque, NM. October, 2013.
33. *Labinov Y, DiDomenico R, Nutescu EA, Cavallari LH.* Comparative accuracy of pharmacogenetic warfarin dosing algorithms and the warfarin dosing label plus clinical judgement. *Pharmacotherapy* 2013;33:e19.[Abstract 28]. 2013 American College of Clinical Pharmacy (ACCP) Annual meeting. Albuquerque, NM. October, 2013.
 34. *Dorsch MP, Lose J, DiDomenico RJ.* Credentialing of cardiovascular pharmacists, process measures, and outcomes. *Circ Cardiovasc Qual Outcomes* 2013;6(Suppl 1):A256. 2013 Quality of Care and Outcomes Research (QCOR) Scientific Sessions. Baltimore, MD. May, 2013.
 35. *Prieto-Centurion V, DiDomenico R, Godwin P, Grude-Bracken N, Gussin H, Jaffe HA, Joo MJ, Markos MA, Nyenhuis S, Pickard AS, Pittendrigh B, Ramey NI, Schatz B, Sullivan J, Thomashow B, Williams MV, Krishnan JA.* A systematic review of interventions to reduce readmissions following COPD exacerbations. *Am J Resp Crit Care Med* 2013;187:A2340. 2013 American Thoracic Society (ATS) International Conference. Philadelphia, PA. May, 2013.
 36. *Kim K, Ardati A, DiDomenico R, Cavallari L, Touchette DR.* Cost-effectiveness of genotype/phenotype driven ticagrelor versus clopidogrel selection in the patients with acute coronary syndrome. *J Am Coll Cardiol* 2014;63(S_12):[Abstract A24]. 63rd Annual American College of Cardiology Scientific Session & Expo. Washington, DC. March, 2014.
 37. *Kim K, Lee TA, Ardati AK, DiDomenico R, Touchette DR, Walton SM.* Comparative effectiveness of ticagrelor vs. prasugrel in patients with acute coronary syndrome. *Value Health* 2015;18:A376[Abstract PCV16]. 18th Annual International Society of Pharmacoeconomic and Outcomes Research (ISPOR) European Congress. Milan, Italy. November, 2015.
 38. *Goncharenko A, Groo VL, Mansour I, Gans C, Stamos T, DiDomenico RJ.* Hospitalization for acute heart failure provides opportunities to intensify chronic therapy for patients with heart failure with reduced ejection fraction. *J Card Fail* 2016;22(Suppl):S98[abstract 284]. Poster presentation: 20th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Orlando, FL. September, 2016.
 39. *Harrington R, Kumar VM, Zueger PM, Rigoni G, Atwood AM, DiDomenico RJ, Touchette DR.* Cost-utility analysis of angiotensin receptor-neprilysin inhibitor sacubitril/valsartan compared with ACE inhibitors for the treatment of chronic heart failure in the United States. *Value in Health* 2016;19:A49[Abstract PCV55]. Poster presentation: 21st Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Washington, DC. May, 2016.
 40. *Kim K, Ardati A, Lee TA, Touchette DR, DiDomenico R, Walton SM.* Contemporary trends and predictors of antiplatelet use in patients with acute coronary syndrome following percutaneous coronary intervention. *J Am Coll Cardiol* 2016;67(S_13):538[Abstract 1133-018]. Poster presentation: 65th Annual American College of Cardiology Scientific Session & Expo. Chicago, IL. April, 2016.
 41. *Tan AY, Mutso A, Pittendrigh B, Edwards D, McGowan D, Calhoun, E, Villareal E, Zaidi, F, Ursan I, Sullivan J, Walsh L, Williams M, Joo M, Kapheim MG, Bracken N, DiDomenico RJ, Pickard AS, Kazmi U, Prieto-Centurion V, Visvabharathy V, Krishnan JA.* How often are patients admitted to the hospital for chronic obstructive pulmonary disease also treated for heart failure and vice versa. *Am J Respir Crit Care Med* 2017;195:A1411. American Thoracic Society (ATS) 2017. Washington, DC. May, 2017.
 42. *Reed BN, DiDomenico RJ, Allender JE, Coons JC, Foster JL, Moretz JD, Oliphant CS, Jennings DL.* Variability in anticoagulation practices with the Impella percutaneous ventricular assist device: a survey of high-volume centers. *J Heart Lung Transplant* 2018;37(Suppl):S310-1[abstract 786]. 38th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT). Nice, France. April, 2018.

Unpublished Abstracts

1. *Tesoro EP, Daughton SE, DiDomenico RJ, Nutescu EA, Lewis RK.* Developing & Implementing a Pharmacist-Managed Antithrombosis Clinic. Poster presentation:

- American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting; New Orleans, LA. December, 1996.
 - University of Illinois at Chicago, College of Pharmacy Enrichment Day; Chicago, IL. April, 1997.
2. *Daughton SE, Tesoro EP, DiDomenico RJ, Nutescu EA, Lewis RK.* Developing and Implementing a Pharmacist-Managed Antithrombosis Clinic. Platform presentation: 12th Annual Great Lakes Pharmacy Resident Conference; Ypsilanti, MI. April, 1997.
 3. *Galanter W, Canonge L, DiDomenico RJ, Kopec K, Looi A, Paek J, Polikaitis A, Thambi M, Welch J.* Alerts to Reduce Medication Errors in In-Patients with Renal Insufficiency. Poster presentation: Chicago Patient Safety Forum 2003 Showcase of Patient Safety Improvements; Chicago, IL. October, 2003.
 4. *Sauve J, Tokumaru S, DiDomenico R, Kao J.* Clinical Outcomes of Patients on Clopidogrel with a Hemorrhagic Episode. Poster presentation: 2005 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2005.
 5. *Lee R, Fontana D, Kondos GT, DiDomenico RJ.* Impact of Nesiritide on Readmission Rates in Patients with Acute Decompensated Heart Failure. Platform presentation: 20th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2005.
 6. *Fontana D, Vuckovic K, DiDomenico R, Kondos GT.* The Effect of Implementation of Medical Center Guidelines on the JCAHO Quality Measures in Patients Hospitalized for HF. Platform presentation: 17th International Nursing Research Congress Focusing on Evidence-Based Practice. Montreal, Quebec, Canada. July, 2006.
 7. *Wiley L, DiDomenico RJ, Shapiro NL, Thambi M, Vacek L, Vitello J, Nutescu EA.* Venous Thrombosis Prophylaxis in Inpatient Bariatric Surgery: A Retrospective, Cohort Evaluation. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.
 8. *Salameh L, Nutescu EA, Kao J, DiDomenico RJ.* Examination of Bleeding Rates in Patients on Long-term Triple Antithrombotic Therapy with Aspirin, Clopidogrel, and Warfarin following Drug-Eluting Stent Placement. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.
 9. *Sauve J, Tokumaru S, DiDomenico R, Kao J.* Clinical Outcomes of Patients on Clopidogrel with a Hemorrhagic Episode. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.
 10. *Tsao YY, Groo VL, Bauman JL, Stamos TD, Viana MAG, DiDomenico RJ.* Comparison of simplified digoxin dosing nomogram to traditional dosing methods in heart failure patients in the modern era. Platform presentation: 22nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2007.
 11. *Dreslinski JA, Paek J, Kao J, DiDomenico RJ.* Comparison of clinical and economic outcomes in patients undergoing percutaneous coronary intervention with bivalirudin with or without glycoprotein IIb/IIIa inhibitors. Platform presentation: 22nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2007.
 12. *Greenhalgh E, DiDomenico RJ.* Predictors of Diuretic Resistance in Patients with Acute Decompensated Heart Failure. Platform presentation: 23rd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2008.
 13. *Na-Thalang K, Tsao YY, Groo VL, Bauman JL, Stamos TD, Viana MAG, DiDomenico RJ.* Comparison of simplified digoxin dosing nomogram to traditional dosing methods in heart failure patients in the modern era. Platform presentation: 23rd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2008.
 14. *Yu S, Galanter WL, Lambert BL, Schiff GD, Borkowsky S for the TOP-MED CERT Team.* Consensus List of Priority Drug-Lab Linkages for an Inpatient Asynchronous Alert Program: Results of a Delphi Survey. Poster presentation: 2009 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2009.

15. Galanter W, Lambert BL, Schiff GD, Nutescu E, Yu S, **DiDomenico RJ**. Monitoring the Risk of Heparin-Induced Thrombocytopenia (HIT) by Linking Laboratory and Pharmacy Data. Poster presentation: Centers for Education and Research on Therapeutics (CERT) Quarterly Meeting. Washington, DC. March, 2009.
16. Bress A, **DiDomenico RJ**, Groo VL, Stamos TD, Cavallari LH. The Effect of Race and Genetic Variants on Diuretic Requirements in Systolic Heart Failure. Poster presentation: 2010 University HealthSystem Consortium (UHC) Pharmacy Council meeting. Anaheim, CA. December, 2010.
17. Dandele LM, Kim KS, **DiDomenico RJ**. Utility of clinical and laboratory data in the identification of heparin-induced thrombocytopenia (HIT). Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.
18. Hall AD, Lee TA, **DiDomenico RJ**. Short-term mortality after inotropic administration in acute decompensated heart failure: a meta-analysis of randomized controlled trials. Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.
19. Musselman ME, Bursua AJ, **DiDomenico RJ**, Shroff A, Groo VL. Prescribing patterns of proton pump inhibitors in patients requiring clopidogrel post-drug eluting stent. Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.
20. Lose J, Dorsch M, **DiDomenico R**. Restrospective cross-sectional analysis comparing hospitals with board of pharmaceutical sciences added qualifications in cardiology certified pharmacists to hospitals without pharmacists with this distinction. Poster presentation: 2011 University HealthSystem Consortium (UHC) Pharmacy Council meeting. New Orleans, LA. December, 2011.
21. Hanigan SM, **DiDomenico R**, Groo VL. Pharmacist-driven hospital-to-home transitional care vs. standard care in patients hospitalized for heart failure. Poster presentation: 2011 University HealthSystem Consortium (UHC) Pharmacy Council meeting. New Orleans, LA. December, 2011.
22. Labinov YA, **DiDomenico RJ**, Stamos TD. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Poster presentation: 2011 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. New Orleans, LA. December, 2011.
23. Hanigan SM, **DiDomenico R**, Groo VL. Pharmacist-driven hospital-to-home transitional care vs. standard care in patients hospitalized for heart failure. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2012.
24. Labinov YA, **DiDomenico RJ**, Stamos TD. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2012.
25. Prieto-Centurion V, **DiDomenico R**, Godwin P, Grude-Bracken N, Gussin H, Jaffe HA, Joo MJ, Markos MA, Nyenhuis S, Pickard AS, Pittendrigh B, Ramey NI, Schatz B, Sullivan J, Thomashow B, Williams MV, Krishnan JA. A systematic review of interventions to reduce readmissions following COPD exacerbations. COPD8USA Conference. Chicago, IL. June, 2013.
26. Labinov YA, **DiDomenico RJ**, Nutescu EA, Cavallari LH. Comparative accuracy of pharmacogenetic warfarin dosing algorithms and the warfarin dosing label plus clinical judgment. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2013.
27. Landup D, **DiDomenico RJ**. Outcomes and utilization of a pharmacy discharge service on 30-day readmission rates in patients hospitalized for acute decompensated heart failure. 28th Annual Great Lakes Resident Conference. West Lafayette, Indiana. April, 2014.
28. Harrington R, Kumar VM, Zueger PM, Rigoni G, Atwood AM, Ochieng W, **DiDomenico RJ**, Touchette DR. Cost-utility analysis of angiotensin receptor-nepriylisin inhibitor LCZ696 to ACE inhibitors for the treatment of chronic heart failure in the United States. Student/resident/fellow non-reviewed: Abstract I20. Association of Managed Care Pharmacy (AMCP) Nexus 2015. Orlando, FL. October, 2015.
29. Ursan I, Krishnan J, Pickard AS, Calhoun E, **DiDomenico R**, Bahroos N, Braken N, Gussin H, Franklin C, Kazmi U, Harvey-Kodish N, Lewis S, MCGowan D, O'Sullivan L, Prieto-Centurion V,

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHFA, FACC
Curriculum Vitae

Site: Columbia/Michael Reese Hospital; Chicago, IL.

2. Global use of strategies to open occluded coronary arteries III (GUSTO III).
GUSTO III Investigators. *New Engl J Med* 1997;337:1118-23.
Boehringer Ingelheim
Role: Local Study Monitor (0%) 1996
Site: Columbia/Michael Reese Hospital; Chicago, IL.
3. Sibrifiban versus aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes (The SYMPHONY Trial)
SYMPHONY Investigators. *Lancet* 2000;335:337-45.
Hoffmann-La Roche, Inc.
Role: Study Coordinator/Local Study Monitor (0%) 1998 – 1999
Site: West Side Veterans Administration Medical Center; Chicago, IL.
4. A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of adenosine (Pallacor, adenosine Injection) as an adjunct to reperfusion therapy (thrombolysis or mechanical reperfusion) in the treatment of acute anterolateral myocardial infarction (AMISTAD II).
AMISTAD II Investigators. *J Am Coll Cardiol* 2005;45:1775-80.
Medco Research, Inc.
Role: Study Coordinator (0%) 1999
Site: University of Illinois Hospital & Health Science System; Chicago, IL
5. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of recombinant P-selectin glycoprotein ligand-Ig in combination with thrombolytic therapy in patients with acute myocardial infarction.
Wyeth-Ayerst Research
Role: Co-I (1%) \$7,769 2000 – 2001
Site: University of Illinois Hospital & Health Science System; Chicago, IL
6. A phase II stratified, randomized, open-label, angiographic trial to assess the safety and efficacy of enoxaparin as an adjunct to thrombolytic with or without GP IIb/IIIa therapy, in patients with ST-elevation MI. The ENTIRE Study.
ENTIRE-TIMI 23 Investigators. *Circulation* 2002;105:1642-9.
Aventis Pharmaceuticals
Role: Co-I (0%) 2000 – 2001
Site: University of Illinois Hospital & Health Science System; Chicago, IL
7. A multicenter, randomized, controlled, double-blind trial to investigate the clinical efficacy and tolerability of early treatment with simvastatin 40mg daily for 30 days, followed by simvastatin 80mg daily thereafter in tirofiban-treated acute coronary syndrome patients who have been randomized to receive enoxaparin or unfractionated heparin in conjunction with aspirin (A to Z).
A to Z Investigators. *JAMA* 2004;292:55-64.
Merck & Co., Inc.
Role: Co-I (1%) \$3,100 2000 – 2003
Site: University of Illinois Hospital & Health Science System; Chicago, IL
8. Acute Decompensated Heart Failure National Registry (ADHERE)
Scios, Inc.
Role: PI (1%) \$46,000 2004 – 2006
Site: University of Illinois Hospital & Health Science System; Chicago, IL
9. Double-blind, placebo-controlled, multicenter Acute Study of Clinical Effectiveness of Nesiritide in subjects with Decompensated Heart Failure (ASCEND-HF)
O'Connor CM, et al. *N Engl J Med* 2011;365:32-43.
Scios, Inc.
Role: Co-I (3%) \$218,750 2007 – 2010

Site: University of Illinois Hospital & Health Science System; Chicago, IL

Unfunded Research

1. *Co-Investigator*. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Completed: 1999.
2. *Principal Investigator*. Impact of nesiritide on readmission and mortality rates in patients with acute decompensated heart failure. Completed 2005.
3. *Co-Investigator*. Impact of real-time medication safety alerts on inpatient prescribing patterns of drugs using a computerized decision support system. Completed 2005.
4. *Co-Investigator*. Predictive value of renal dysfunction and low blood pressure on six month mortality and readmission in patients hospitalized for acute decompensated heart failure. Completed 2006.
5. *Co-Investigator*. Impact of treatment guidelines on compliance with JCAHO Core measures for patients hospitalized with acute decompensated heart failure. Completed 2006.
6. *Co-Investigator*. Impact of nesiritide on renal function in patients with acute decompensated heart failure. Completed 2006.
7. *Co-Investigator*. Comparison of pharmacokinetic dosing regimens for digoxin. Completed 2006.
8. *Principal Investigator*. Examination of bleeding rates in patients on long-term triple antithrombotic therapy with aspirin, clopidogrel, and warfarin. Completed 2007.
9. *Principal Investigator*. Incidence and predictors of diuretic resistance in patients with acute decompensated heart failure. Completed 2008.
10. *Principal investigator*. Factors associated with rehospitalization for heart failure. Completed 2010.
11. *Principal investigator*. Mortality associated with use of inotropic agents in patients with acute decompensated heart failure: a meta-analysis. Completed 2010.
12. *Co-Investigator*. Use of laboratory and pharmacy linkages to identify possible heparin-induced thrombocytopenia. Completed 2010.
13. *Co-Investigator*. Specificity of administrative data for identifying heart failure patients for hospital quality performance measures. Completed 2010.
14. *Co-Investigator*. Pharmacist-driven hospital-to-home transitional care vs. standard of care in patients hospitalized for heart failure. Completed 2012.
15. *Co-Investigator*. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Completed 2012.
16. *Co-Investigator*. Prescribing patterns of proton pump inhibitors in patients having percutaneous coronary intervention on chronic clopidogrel therapy. Completed 2012.
17. *Co-Investigator*. Torsemide versus furosemide plus metolazone for symptomatic chronic heart failure. Completed 2012.
18. *Co-Investigator*. Comparative accuracy of genotype-based warfarin dosing algorithm and clinical judgment. Completed 2013.
19. *Co-Investigator*. Estimation of the net clinical benefit and the risk of stroke and hemorrhagic events in patients with atrial fibrillation. Completed 2013.
20. *Co-Investigator*. Outcomes and utilization of a pharmacy discharge service on 30-day readmission rates in patients hospitalized for acute decompensated heart failure. Completed 2014.
21. *Co-Investigator*. Appropriate use of IV diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter. Completed 2015.

22. *Co-Investigator*. Restrospective cross-sectional analysis comparing hospitals with board of pharmaceutical sciences added qualifications in cardiology certified pharmacists to hospitals without pharmacists with this distinction. Completed 2015.
23. *Co-Investigator*. Trends in medication intensification during hospitalization for acute decompensated heart failure. 2015 – present.
24. *Co-Investigator*. Risk evaluation and prediction of cardiac events among azithromycin users (BEATS: Better Evidence of Azithromycin Treatment & Safety). 2015 – present.
25. *Co-Investigator*. Impella anticoagulation management survey. 2016 – 2018.
26. *Co-Investigator*. Impact of upstream vs deferred decision of clopidogrel administration in patients with non-ST-elevation myocardial infarction. 2016 – 2018.
27. *Co-Investigator*. Addition of oral metolazone to intermittent intravenous furosemide versus transition to continuous infusion furosemide in acute decompensated heart failure patients experiencing an inadequate response to therapy. Terminated 2017.
28. *Co-Investigator*. Cost-utility analysis of angiotensin receptor-neprilysin inhibitor sacubitril/valsartan compared to ACE inhibitors for the treatment of chronic heart failure in the United States. Completed 2017.
29. *Co-Investigator*. Insight into the ADP pathway inhibitor use in patients with ACS. Completed 2017.
30. *Co-Investigator*. Evaluation of triple vs. dual antithrombotic therapy in patients with PCI: sequence of events and it's influence on prescribing patterns. 2017 – 2018.

INVITED LECTURES

International

1. "Health economics and outcomes research workshop." Five day, team-taught continuing education program introducing the topics of health economics and outcomes research to pharmacists and faculty members in Thailand. Khon Kaen, Thailand. January 2003.
 - Lecture topics: *Motivations for Economic Evaluations and Outcomes Research, Cost-Minimization Analysis, Drug Utilization Review/Evaluation, Modeling & Decision Analysis, Evaluating Pharmacoeconomic Literature, Clinical Pathways, Applying Results.*
2. "Transitions of care and pharmacist services" Given as part of the American College of Clinical Pharmacy (ACCP) 2015 From Theory to Bedside: Clinical Reasoning Series entitled "Heart Failure: Current and Emerging Management Strategies" during the 2015 ACCP Global Conference on Clinical Pharmacy: 0.6 CEU (ACPE Universal Program # 0217-0000-15-111-L01-P). San Francisco, CA. October, 2015.
3. "Treatment of acute cardiovascular diseases". 3-day series of lectures and case workshops as part of the Hong Kong University Master of Clinical Pharmacy program. Pokfulam, Hong Kong. October, 2017.
 - Lecture topics: *Cardiovascular Assessment, IV Vasoactive Drugs, Hypertensive Crisis, Acute Coronary Syndrome, Acute Decompensated Heart Failure, Pharmacotherapy of Shock, Acute Treatment of Atrial Fibrillation & Atrial Flutter.*
4. "Starting with the end in mind: Planning & executing your research project". Presented as part of a session entitled "Perfecting your poster presentations" during the 2018 American College of Clinical Pharmacy (ACCP) Global Conference: 1.5 CEU. Seattle, WA. October, 2018.

National

1. "Late-Breaking clinical trials in cardiovascular pharmacotherapy: ELITE II Study." American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program #217-000-00-054-L01). Los Angeles, CA. November, 2000.
2. "Innovative reimbursement strategies in acute coronary syndrome." Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #: 510-000-01-035-L01). New Orleans, LA. December, 2001.

3. "Combining GP IIb/IIIa inhibitors with fibrinolytics in acute ST segment elevation MI." American College of Clinical Pharmacy (ACCP) Spring Practice & Research Forum: 0.275 CEU (ACPE Universal Program #217-000-02-017-L01). Savannah, GA. April, 2002.
4. "The use of colloids and antithrombotics during open-heart surgery." American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-02-238-L01). Atlanta, GA. December, 2002
5. "The closed loop medication management experience." Series of demonstrations showing the utility of the decision support mechanisms developed at the University of Illinois Medical Center. Healthcare Information and Management Systems Society 2003 Annual Conference & Exhibition. San Diego, CA. February, 2003.
6. "Guidelines for the management of acute decompensated heart failure in the emergency department or observation unit." Mercy Resource Management, Inc. Clinical Resource Committee. San Diego, CA. May, 2003.
7. "Acute decompensated heart failure: can I get some guidance?" Satellite symposium at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). Atlanta, GA. November, 2003.
8. "Acute decompensated heart failure: where does nesiritide fit in?" Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). New Orleans, LA. December, 2003.
9. "Strategies for preventing atrial fibrillation in the perioperative setting." American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-03-239-L01). New Orleans, LA. December, 2003.
10. "Acute decompensated heart failure: evolution of treatment guidelines." Guest speaker at the Scios, Inc. National Sales Meeting 2004. New Orleans, LA. April, 2004.
11. "Acute decompensated heart failure: early goal directed therapy." 3 separate live audio teleconferences to members of the Premier, Inc. healthcare system: 0.1 CEU (ACPE Universal Program # 221-000-04-014-L01). July, 2004.
12. "The pharmacist's perspective on emergency management of heart failure." Live webcast broadcast nationally to emergency medicine clinicians across the United States as part of a series from the Cleveland Clinic Center: 0.15 CEU (ACPE Universal Program #073-999-04-135-C01). Cleveland, OH. October, 2004.
13. "Acute decompensated heart failure: proposed treatment guidelines." Focus Group on the IHN Perspectives of Disease State Management of Congestive Heart Failure for members of Novation/VHA/UHC. Sponsored by Scios, Inc.. Irving, TX. March, 2005.
14. "Hypertension, metabolic syndrome, and JNC guidelines: reassessing treatment guidelines." American Pharmacists Association (APhA) Foundation National Clinical Issues Forum on Metabolic Syndrome: 0.1 CEU (ACPE Universal Program #202-000-05-168-L01). Lake Bluff, IL. May, 2005.
15. "Evaluating acute decompensated heart failure treatment: from nesiritide MUE to ADHF guidelines." Scios, Inc. National Pharmacy Advisory Board. San Francisco, CA. June, 2005.
16. "Managing ADHF: resource utilization and cost containment." Live webcast broadcast nationally to heart failure clinicians across the United States: 0.15 CEU. July, 2005.
17. "Acute decompensated heart failure: strategies to improve clinical and economic indicators." Live webcast broadcast nationally to members of McKesson Medication Management, LLC and Purchasing Alliance for Clinical Therapeutics. Continuing education credit: 0.1 CEU. August, 2005.
18. "Pathway development and pharmacoeconomics of acute decompensated heart failure treatment." Presented & chaired a satellite symposium on "Current and Emerging Issues in the Management of Acute Decompensated Heart Failure" for Continuing Education: 0.2 CEU (ACPE Universal Program #204-000-05-419-L01). American College of Clinical Pharmacy (ACCP) Annual Meeting. San Francisco, CA. October, 2005.

19. "Using critical pathways and pharmacoeconomics to guide ADHF treatment decisions" Presented & chaired a satellite symposium on "Acute Decompensated Heart Failure: Current and Emerging Issues Influencing Treatment Strategies" for Continuing Education: 0.25 CEU (ACPE Universal Program #204-000-05-420-L01). American Society of Health-System Pharmacy (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2005.
20. "Pharmacologic management of atrial fibrillation." American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-05-218-L01). Las Vegas, NV. December, 2005.
21. "Current controversies in the management of acute decompensated heart failure." Presented as a national teleconference for pharmacists. April, 2006.
22. "The nesiritide controversy: if there's smoke, is there fire?" Satellite symposium at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program # 786-000-06-010-L01). St. Louis, MO. October, 2006.
23. "Future directions in ADHF treatment: unresolved issues and emerging evidence." Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.25 CEU (ACPE Universal Program # 204-000-06-459-L01). Anaheim, CA. December, 2006.
24. "Determining the value of pharmacy intervention/services in an acute care hospital setting" American College of Clinical Pharmacy (ACCP) Spring Practice & Research Forum: 0.2 CEU (ACPE Universal Program #217-000-08-030-L04-P). Phoenix, AZ. April, 2008.
25. "Update in the management of chronic stable angina and the role of the pharmacist." American Pharmacists Association (APhA) Annual Meeting: 0.2 CEU (ACPE Universal Program #217-000-08-030-L04-P). San Antonio, TX. April, 2009.
26. "Implementing quality measures across the continuum: success in the inpatient setting." American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.15 CEU (ACPE Universal Program #0217-0000-12-105-L04-P). Hollywood, FL. October, 2012.
27. "Heart health: hypertension, cardiac, and hypercholesterolemia." Gerontological Advanced Practice Nurses Association (GAPNA) Pre-Conference Workshop. Chicago, IL. September, 2013.
28. "Perspectives on reducing readmission." 2013 Heart Failure Society of America Heart Failure (HFSA) Comprehensive Review & Update. Chicago, IL. November, 2013.
29. "Therapeutic considerations in heart failure patients with anemia." Presented and moderated "How to manage comorbidities in heart failure: depression, sleep apnea, and anemia." 2013 Heart Failure Society of America (HFSA) Heart Failure Comprehensive Review & Update. Chicago, IL. November, 2013.
30. "Evaluating the evidence: clinical guidelines on secondary prevention." Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.2 CEU (ACPE Universal Program #0245-0000-13-023-L01-P). Orlando, FL. December, 2013.
31. "A pharmacist's perspective on dosing considerations for novel oral anticoagulants in venous thromboembolism and prevention of atrial fibrillation-related stroke." Panelist for a videotaped continuing education satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.050 CEU (ACPE Universal Program #0461-0000-14-004-H01-P). Orlando, FL. December, 2013.
32. "Hypertensive emergencies." Panelist for this Pharmacology Program as part of the 63rd Annual American College of Cardiology (ACC.15) Scientific Sessions. Washington, DC. March, 2014.
33. "The beta-adrenergic receptor post-MI: beta-blocker use should continue." Part of a pro/con debate. 64th Annual American College of Cardiology Scientific Session & Expo. San Diego, CA. March, 2015.
34. "New cardiovascular drugs: out with the old, in with the new?" Live webinar to members of Community Health Systems. ProCE, Inc.: 0.2 CEU. Bartlett, IL. May, 2015.

35. "Case discussion-clinical conundrums". Panelist for session at the 19th Annual Heart Failure Society of America (HFSA) Scientific Meeting. National Harbor, MD. September, 2015.
36. "PCSK9 inhibitors and entresto: who should get these expensive new drugs and what are the economic implications?" Panelist for this Pharmacology Program as part of the 65rd Annual American College of Cardiology (ACC.16) Scientific Sessions. Chicago, IL. April, 2016.
37. "Treatment considerations in HF patients with cognitive disorders." Presented as part of the Clinical Fundamentals III session entitled "Cognitive Deficits in HF: Chicken or the Egg?" 20th Annual Heart Failure Society of America (HFSA) Scientific Meeting. Orlando, FL. September, 2016.
38. "Contemporary approaches to the management of chronic heart failure: an overview." American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-16-463-L01-P; 0204-0000-16-463-H01-P). Chicago, IL. October, 2016.
39. "Do's and don'ts during peer review." Presented and served on panel for session entitled "The Best of Times, The Worst of Times: Navigating the Peer Review Process." American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0271-0000-16-155-L04-P). Las Vegas, NV. December, 2016.
40. "New and emerging strategies for the treatment of chronic heart failure: a clinical case studies workshop." Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-16-467-L01-P; 0204-0000-16-467-H01-P). Las Vegas, NV. December, 2016.
41. "The pharmacist's role in optimizing outcomes for heart failure." Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-17-016-L01-P). Webinar (August, 2017).
42. "Improving the management of chronic heart failure during transitions of care." American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-17-436-L01-P; 0204-0000-17-436-H01-P). Chicago, IL. September, 2017.
43. "Cardiology PRN focus session—practical approaches to heart failure management across the continuum of care". Moderated session at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.15 CEU (ACPE Universal Program #0217-0000-17-159-L01-P). Phoenix, AZ. October, 2017.
44. "Better management of chronic heart failure through better transitions of care: a clinical case studies workshop." Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-17-437-L01-P; 0204-0000-17-437-H01-P). Orlando, FL. December, 2017.
45. "Challenging cases in diabetes management in heart failure." Presented as part of a symposium entitled "750 – Sweetening the Pill: New Options for Treating Diabetes in Heart Failure" at the 67th Annual Scientific Session & Expo of the American College of Cardiology (ACC.18). Orlando, FL. March, 2018.
46. "To dig or not to dig." Presented as part of the session entitled "Help or Harm? Common Controversies in the Management of HF" at the 22nd Annual Heart Failure Society of America (HFSA) Scientific Meeting. Nashville, TN. September, 2018.
47. "Sodium restriction in heart failure: worth its salt? Pro." Presented as part of the session entitled "Fact or Fiction: Clinical Controversies in Heart Failure" at the American Heart Association (AHA) Scientific Sessions 2018. Chicago, IL. November, 2018.
48. "Getting back to basics: The evidence for what works in the management of chronic heart failure." Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-18-447-L01-P; 0204-0000-18-446-H01-P). Anaheim, CA. December, 2018.

49. "Ask the experts: building a toolkit for managing heart failure." American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-19-405-H01-P). Chicago, IL. March, 2019.

Local/Regional

1. "Does Growth Hormone Have a Role in the Treatment of Congestive Heart Failure?" University of Illinois at Chicago, College of Pharmacy. Chicago, IL. November, 1996.
2. "Are Appetite Suppressants (Anorexics) Safe in Patients with Cardiovascular Disease?" Michael Reese Hospital. Chicago, IL. May, 1997
3. "Use of Digoxin Immune Fab for Non-Life-Threatening Digoxin Toxicity." University of Illinois at Chicago College of Medicine, Section of Cardiology Research Conference. Chicago, IL. September, 1998.
4. "Digoxin Immune Fab: An Alternative to Minimize the Costs of Treating Non-Life-Threatening Digoxin Intoxication." February, 1999.
 - University of Nebraska (Omaha, NE), University of Missouri-Kansas City (Kansas City, MO), & Texas Tech University (Amarillo, TX).
5. "Clinical Pharmacology of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors." Illinois Pharmacy Spring Congress: 0.15 CEU (ACPE Universal Program Number 121-888-99-024-L01b). Springfield, IL. April, 1999.
6. "Glycoprotein IIb/IIIa Inhibitors: Where Do They Fit In?" University of Illinois at Chicago College of Pharmacy: 0.3 CEU (ACPE Universal Program Number 016-000-99-050-L04). Oak Brook, IL. November, 1999.
7. "Tikosyn™ (dofetilide) Clinical Profile." Tikosyn™ Faculty Educator as part of the Tikosyn™ Medical Education Program regionally within the Midwestern United States. July, 2000 – 2001.
8. "Lipid-Lowering Drugs & Cardiovascular Event Reduction: Beyond Improved Lipid Profiles." Illinois Pharmacy Fall Congress: 0.1 CEU (ACPE Program Number 135-121-00-068-L01). Oakbrook, IL. September, 2000.
9. "Pharmacology Update for the Perfusionist: New Antithrombotic Drugs." Chicago Educational Symposium for Cardiac Perfusionists. Chicago, IL. October, 2000.
10. "Diagnosis and Treatment of Hypertension." Novartis II and Novartis III Center of Excellence Design. Chicago, IL. February, 2001 - 2006.
11. "Building Community...Using Mentoring." University of Illinois at Chicago College of Pharmacy 2001 Faculty Retreat: 0.15 CEU (ACPE Universal Program Number 016-000-01-026-L04). St. Charles, IL. May, 2001.
12. "Antiplatelet Therapy in the Management of Acute Coronary Syndromes: Use of Chronic Medications for Acute Coronary Syndromes: Antiplatelets & Statins." Phi Delta Chi Alumni Association: 0.15 CEU (ACPE Universal Program Number 316-000-99-022-L01). Oak Brook, IL. November, 2001.
13. "Heparin-Induced-Thrombocytopenia and Anticoagulation During Cardiopulmonary Bypass." Illinois State Perfusion Society Meeting. Chicago, IL. April, 2002.
14. "Acute Decompensated Heart Failure: Current Therapies and Proposed Guidelines." Mercy Resource Management, Inc. Clinical Resource Committee. Chicago, IL. April, 2003.
15. "Medications Ordered During Pregnancy that Affect Cardiac Function." Nursing Staff Development. University of Illinois at Chicago, College of Nursing. Chicago, IL. June, 2003 - 2005.
16. "Pharmacology of Vasoactive & Antiarrhythmic Drugs Commonly Used in the ICU." Nursing Staff Development Critical Care. University of Illinois Medical Center. Chicago, IL. June, 2003 – 2008.
17. "Rational Approach to Vasoactive Pharmacotherapy." University of Illinois at Chicago: 0.1 CEU (ACPE Universal Program Number 121-000-03-045-L01). Chicago, IL. July, 2003.

18. "Acute Decompensated Heart Failure: Early Goal Directed Therapy": 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). Memphis, TN. March, 2004.
19. "Metabolic Syndrome: A New Target in Preventative Cardiology." Illinois Council for Health-System Pharmacists (IHP) Spring Meeting: 0.3 CEU (ACPE Universal Program Number 121-000-04-012-L01). Springfield, IL. March, 2004.
20. "Medication Madness: New Drugs for Cardiac Care." Guest speaker at the Minneapolis Heart Institute 6th Annual Hutchinson Regional Cardiovascular Nursing Conference. Hutchinson, MN. April, 2004.
21. "Opening the Therapeutic Window in Acute Decompensated Heart Failure: Closing in on the Value of Nesiritide." University Pharmacotherapy Associates, LLC: 0.1 CEU (ACPE Universal Program # 786-000-03-006-L01). May – October, 2004.
 - Indianapolis, IN; Suffern, NY; Providence, RI; Palos Park, IL; Princeton, NJ (New Jersey Society Health-System Pharmacy North Central Chapter meeting).
22. "Metabolic Syndrome: A New Target in Preventative Cardiology." Abbott Cardiovascular Medical Science Liaisons. Chicago, IL. July, 2004.
23. "Treatment Guidelines for Acute Decompensated Heart Failure: Design and Implementation." Dearborn, MI. September, 2004.
24. "Anticoagulation Interruptus: Low-Molecular-Weight Heparin Bridging in Patients with Prosthetic Heart Valves." University of Illinois at Chicago College of Medicine, Section of Cardiology for CME credit. Chicago, IL. November, 2004.
25. "Life as a Clinical Pharmacist." American Pharmaceutical Association Academy of Student Pharmacists at the University of Illinois at Chicago College of Pharmacy. Chicago, IL. November, 2004.
26. "Acute Myocardial Infarction: Get with the Guidelines!" University of Illinois at Chicago: 0.1 CEU (ACPE Universal Program Number 121-999-05-031-L01). Chicago, IL. March, 2005.
27. "Therapeutic Advances in Acute Decompensated Heart Failure." University Pharmacotherapy Associates, LLC: 0.1 CEU (ACPE Universal Program # 786-000-03-006-L01). April, 2005 – September, 2005.
 - Southfield, Michigan; Oklahoma City, Oklahoma; Carle Place, New York (c/o Long Island Society of Health-System Pharmacy monthly meeting); Libertyville, IL; Rosemont, Illinois.
28. "Evaluating Acute Decompensated Heart Failure Treatment: From Nesiritide MUE to ADHF Guidelines." Scios, Inc. Regional Pharmacy Advisory Board. Chicago, IL. July, 2005.
29. "The Nesiritide Controversy: Media-Based Medicine or Evidence-Based Medicine." University of Illinois at Chicago College of Medicine, Section of Cardiology. Chicago, IL. September, 2005.
30. "Achieving Hemostasis in the Critically Ill Patient." Program chair & moderator: 0.2 CEU (ACPE Universal Program Number 221-000-05-045-L01). Oak Brook, IL. October, 2005.
31. Acute Decompensated Heart Failure: Strategies to Improve to Improve Clinical and Economic Indicators." Consorta 2005 Annual Resource Management Conference: 0.1 CEU. Chicago, IL. October, 2005.
32. "Influence of Treatment Strategy on Six-Month Mortality and Readmission in Patients Hospitalized for Acute Decompensated Heart Failure." University of Illinois at Chicago Department of Pharmacy Practice Research Seminar series. Chicago, IL, January, 2006.
33. "Acute Decompensated Heart Failure: Lessons from ADHERE®". Oak Brook, IL. June, 2006.
34. "Digoxin Dosing in the Modern Era for Patients with Chronic Heart Failure." University of Illinois at Chicago College of Medicine, Section of Cardiology for CME credit. Chicago, IL. November, 2006.
35. "Diuretic Resistance in Heart Failure." University of Illinois at Chicago College of Medicine, Section of Cardiology for CME credit. Chicago, IL. January, 2008.

36. "Engaging Clinical Faculty in Scholarship." 2008 University of Illinois College of Pharmacy Faculty Retreat: 0.2 CEU (ACPE Universal Program Number 016-000-08-017-L04-P). Fontana, WI. May, 2008.
37. "PDAT Coordination – Developing Standard Practices." 2010 University of Illinois College of Pharmacy Faculty Retreat: 0.2 CEU (ACPE Universal Program Number 016-000-08-017-L04-P). Fontana, WI. May, 2010.
38. "Medications and the Perfusionist: Is the Glass Half-Full or Half-Empty?" Illinois State Perfusion Society Meeting. Oak Brook, IL. October, 2010.
39. "Heparin Grand Rounds." Nursing Staff Development. University of Illinois Medical Center. Chicago, IL. March, 2011.
40. "Pharmacotherapy for Acute Coronary Syndromes & Acute Decompensated Heart Failure." University of Illinois at Chicago College of Medicine Section of Cardiology. Chicago, IL. September, 2011.
41. "The Role of a Facilitator to Engage Students in Recitation Sessions." University of Illinois at Chicago College of Pharmacy: 0.2 CEU (ACPE Universal Program Number 016-000-11-136-L01-P). Rockford, IL. October, 2011.
42. "New and Emerging Antithrombotic Therapies for Patients with Acute Coronary Syndrome." 2011 University of Illinois at Chicago College of Pharmacy CPE Fall Summit: 0.1 CEU (ACPE Universal Program Number 016-000-11-113-L01-P). Chicago, IL. October, 2011.
43. "Health Professions Student Council Leadership Series Round Table." Health Professions Student Council members: role of the clinical pharmacist. University of Illinois at Chicago College of Pharmacy. Chicago, IL. November, 2011.
44. "UIC Curriculum Revision Update." Presented to University of Illinois at Chicago College of Pharmacy National Advisory Board. Chicago, IL. April, 2012.
45. "Writing Quality Self-Assessment Questions." Part of panel discussion. University of Illinois at Chicago College of Pharmacy Residency Teaching Program. Chicago, IL. May, 2012.
46. "Implementation of Clopidogrel Pharmacogenetics at the University of Illinois Hospital & Health Sciences System." Part of panel discussion. University of Illinois at Chicago College of Pharmacy: 0.1 CEU (ACPE Universal Program Number 0016-0000-12-082-L01-P). Chicago, IL. June, 2012.
47. "Novel Oral Anticoagulants for Venous Thrombosis and Atrial Fibrillation: Implications for Clinical Practice." University of Illinois at Chicago College of Pharmacy: 0.1 CEU (ACPE Universal Program Number 0016-0000-12-082-L01-P). Chicago, IL. August, 2012.
48. "Don't Be Left Out in the Cold: Pharma Update." 5th Annual Illinois Chapter American College of Cardiology (ACC) Cardiac Care Associate Symposium. Lombard, IL. November, 2012.
49. "Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty in the US. University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice Faculty Development Seminar Series. Chicago, IL. February, 2013.
50. "Standardizing the Principles of Drug Action and Therapeutics (PDAT) series of courses in the PharmD curriculum". 2013 University of Illinois College of Pharmacy Faculty Retreat. Fontana, WI. May, 2013.
51. "Transitions: Preparing Your Learners for Their Next Steps". 2013 University of Illinois at Chicago College of Pharmacy Preceptor Conference: 0.1 CEU (ACPE Universal Program Number 0016-0000-13-104-L04-P). Chicago, IL. May, 2013.
52. "CAPs: Creating Anticoagulation Plans to Prevent Stroke in Patients with Atrial Fibrillation." Paradigm Medical Communications. Austin, TX; Quincy, IL. June – August, 2013.
53. "Opportunities for Pharmacy to Impact Inpatient Quality Measures." Illinois Council of Health System Pharmacists (IHP) 2013 Annual Meeting: 0.1 CEU (ACPE Universal Program Number 0121-0000-13-053-L05-P). Oakbrook Terrace, Illinois. September, 2013.

54. "UIC New Curriculum Preview." 2015 University of Illinois at Chicago College of Pharmacy Preceptor Conference: 0.05 CEU. Chicago, IL. May, 2015.
55. "Curricular Revision Update". 2015 University of Illinois College of Pharmacy Faculty Retreat. Fontana, WI. May, 2015.
56. "Curricular Change at UIC: Fruits of a Slow but Steady Process of Faculty Engagement." University of Wisconsin School of Pharmacy. Madison, WI. November, 2015.
57. "JNC 8 Guideline for Hypertension: Was It Worth The Wait?" Rockford Memorial Hospital Grand Rounds. Rockford, IL. May, 2016.
58. "Practice-Based Approach to Heart Failure Research." University of Nebraska College of Pharmacy. Omaha, NE. March, 2016.
59. "The pharmacist's role in optimizing outcomes for heart failure." Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-17-016-L01-P). Princeton, NJ (March, 2017); Dallas, TX (April, 2017).
60. "Using Practice-Based Research to Resolve Drug-Related Problems & Identify Opportunities for Pharmacists". Haim G. and Jane Graumann Nagirner Weinstein Symposium Series Speaker. Rosalind Franklin University of Medicine and Science College of Pharmacy. North Chicago, IL. November, 2017.
61. "Developing successful research collaborations: turning practice into scholarship." Faculty development seminar for members of the University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice. Chicago, IL. April, 2018.
62. "Lessons in precepting pharmacy trainees." Palmetto Health Richland. Columbia, SC. October, 2018.
63. "Clinical controversies in the management of acute heart failure." South Carolina Society of Health-System Pharmacists (SCSHP) Fall meeting: 0.1 CEU. Columbia, SC. October, 2018.
64. "Improving transitions of care in heart failure: the role of health-systems and community pharmacists." Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-19-033-L01-P). Chicago, IL (March, 2019); Anaheim, CA (April, 2019); Nashville, TN (May, 2019), New Brunswick, NJ (June, 2019).

ORGANIZATIONAL MEMBERSHIPS

1996 – 2010	Illinois Council of Health-System Pharmacists (IChP)
2008 – 2009	IChP/Missouri Society of Health-System Pharmacists (MSHP) 2009 Spring Meeting Planning Committee
1996 – present	American Society of Health-System Pharmacists (ASHP)
2000 – 2006	Network Resource Contact
2005 – present	Section on Clinical Specialists and Scientists
2006 – 2009	ASHP Research and Education Foundation Antithrombotic Pharmacotherapy Traineeship Main Co-Preceptor
2013	Survey Panel for the Pharmacy Forecast 2014 – 2018 report (ASHP Foundation Center for Health-System Pharmacy Leadership)
2013	PGY2 Cardiology Pharmacy Residency program Site Surveyor
2016 – 2017	PGY2 Cardiology Residency Goals & Objectives Revision Workgroup (ACCP representative)
1997 – present	American College of Clinical Pharmacy (ACCP)
1997 – present	Cardiology PRN

**Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae**

	2008 – 2009	Editorial liaison for <i>Cardiology Today</i>
	2008 – 2012	Awards and Recognition Committee
	2011	Cardiology PRN & American Heart Association Focus Session Content Reviewer
	2012	Heart to Heart program
	2012 – 2013	Expenditures Committee
	2012 – 2013	2013 Focus Session Programming Committee
	2013 – 2014	Budget and Finance Committee
	2014 – 2015	Research and Scholarship Committee
	2018 – present	
	2014 – present	Mentorship Program
	2015 – 2017	Programming Committee
	2017 – 2018	Nominations Committee
	2019 – present	eJournal Club mentor
	1997 – 2007	Critical Care PRN
	2001 – 2007	Outcomes and Economics PRN
	2007 – 2009	Heart Failure Traineeship Site Director
	2012	Clinical Pharmacy Challenge Item Writer
	2012 – 2018	Practice-Based Research Network (PBRN),
	2014 – 2018	Community Advisory Panel
	2013	Inpatient Clinical Pharmacist Focus Group
	2013 – 2014	Certification Affairs Committee
	2016	Grant reviewer, Research Institute Futures Grants & Junior Investigator Grant
	2019	Clinical Research Challenge Review Committee
2001 – present		Rho Chi Society , Phi Chapter
2004 – 2008		University Pharmacotherapy Associates, LLP (UPA) National Consensus Faculty
	2004 – 2006	Acute Decompensated Heart Failure programs
	2007 – 2008	Acute Coronary Syndrome programs
2005 – present		Heart Failure Society of America (HFSA)
	2014 – present	Research Committee
	2016 – 2017	Annual Speed Mentoring Session Mentor
	2018 – present	Programming Committee (2019 Annual Meeting)
2007		National Association of Boards of Pharmacy® (NABP®) Item Writing Workshop for the North American Pharmacist Licensure Examination™ (NAPLEX®)
2011 – 2014		American Heart Association (AHA) , Midwest Affiliate
	2002 – 2004	American Heart Association (AHA) Get With the Guidelines Consortium
	2011 – 2014	Council on Clinical Cardiology
	2011 – 2014	Council on Quality of Care and Outcomes Research
2012 – 2015		Phi Lambda Sigma Pharmacy Leadership Society, <i>Alpha Iota</i> chapter
	2013 – 2015	Lunch with a Pharmacist Host

2012 – present	American College of Cardiology (ACC)
	2012 – present Cardiovascular Team Member Section
	2014 – present Clinical Pharmacists Work Group
	2015 – present ACC Cardiovascular Pharmacists Poster Session Planning Committee
	2017 – present CardioSurve Research Panel
2017 – present	Board of Pharmacy Specialties (BPS)
	2017 – present Appointed member, Inaugural BPS Specialty Council on Cardiology
2018 – present	American Association of Colleges of Pharmacy (AACP)

COMMITTEE MEMBERSHIP

University of Illinois Hospital & Health Sciences Center

1999 – 2002	6WSD/CICU Quality Assurance/Improvement Committee
1999 – 2004	Hospital Pharmacy Services Committees
	2003 – 2004 Pharmacy Advisory Group
	2003 – 2004 Ad-Hoc Committee for medications requiring special monitoring
	2000 – 2001 Medication Use Evaluation Committee
	1999 – 2000 Pharmacy Council
1999 – 2005	Emergency Cardiac Care Committee
	2004 – 2005 Protective Code Subcommittee
2001 – 2002	JCAHO Patient Assessment Task Force
2001 – 2004	Clinical Decision Support Committee
2003 – 2006	Cardiovascular Quality Improvement Committee Departments of Medicine (Section of Cardiology) & Surgery (Division of Cardiothoracic Surgery)
2003 – 2013	Cardiovascular (CV) Quality Improvement (QI) Committee
	2009 – 2010 CV QI Committee Subcommittee on 30-day readmissions
2005	Sentinel Event Clinical Review Team
2006 – 2007	Perioperative Beta-Blockade Committee
2009 – 2014	Journal Club Facilitator University of Illinois at Chicago, College of Medicine Housestaff Physicians
2010, 2014, 2017	Key Content Expert, G-1.01. Acute Coronary Syndromes Clinical Care Guideline
2011, 2014	Key Content Expert, G-1.02. Adult Heart Failure Management Clinical Care Guideline
2012 – 2013	Healthcare Delivery Grants and Contracts Review Board
2013 – 2016	Heart Failure Readmission Team
2013 – 2014	Readmissions Clearinghouse
2013 – 2014	Project BOOST Core Team
2018 – present	Discovery Partners Institute (DPI) Health Topic Advisory Board (Illinois Innovation Network, IIN)

University of Illinois at Chicago College of Pharmacy

2000 – present	Department of Pharmacy Practice Committees
	2000 – 2007 Pharmacy Practice Resident Seminar Evaluation Committee

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae

	2000 – present	Various Search Committees
	2005	Strategic Planning Committee
	2005	Part-Time Faculty Ad-Hoc Committee
	2006 – 2012, 2014 – present	Faculty Advisory Committee
	2006 – 2008	Educational Policy Committee
	2007 – 2009	Residency Noon Report Committee
	2008 – 2012	Institutional Review Board Internal Review Committee
	2009 – 2010, 2013	Research Strategic Planning Committee
	2013 – 2015	Mid-career Faculty Development Committee
	2014 – 2016	Promotion and Tenure Ad Hoc Committee
	2015 – present	Promotion and Tenure Committee
2004 – 2006, 2008 – 2018	Educational Policy Committee (elected member, 2008 – 2018)	
	2004	Pharmacy Practice Subcommittee
	2005 – 2006	Pharmacokinetics Working Group
	2008 – 2015	Rockford Expansion Subcommittee
	2008 – 2012	Teaching Evaluation Subcommittee
	2010 – 2015	Rockford Policies Subcommittee
	2015 – 2018	New Curriculum Implementation Subcommittee
2006 – 2007	American Council for Pharmaceutical Education (ACPE) Self-Study Committee	
2007 – 2012	Residency Research Committee	
	2010 – 2011	Clinical Tenure Track Ad-hoc Committee
2008 – 2018	Student Faculty Relations Committee	
2008 – 2009	Thesis Dissertation Defense Committee (Candidate: Alexandra Perez)	
2008 – 2010	Continuing Education Advisory Committee	
2009	Assistant Head for Academic Affairs Search Committee	
2010 – 2011	Task Force on Teaching Mission and Faculty Teaching Load	
2010 – 2011	College of Pharmacy Research Day poster judge	
2011 – 2015	Curricular Revision Steering Committee	
	2011 – 2013	Experiential Education Subcommittee
	2014 – 2015	Phase III-Curriculum Development
2013	Riback Award Review Committee	
2013	PhD Preliminary Committee (Candidate: Kibum Kim)	
2013 – 2014	American Council for Pharmaceutical Education (ACPE) Self-Study Committee	
2014	Faculty Focus Group for the College of Pharmacy Teaching & Learning Center	
2016	Director of Assessment Search Committee	
2017 – 2018	Senior Instructional Designer Search Committee	
2018 – present	Curricular Assessment Committee	
2018 – present	Head, Department of Pharmacy Practice Search Committee	

MENTORING ACTIVITIES

University of Illinois at Chicago College of Pharmacy

TEACHING EXPERIENCE

University of Malta International Collaborative Programmes Doctorate in Pharmacy

2018 – present Pharmacotherapeutics II (PHR5617)

University of Illinois at Chicago College of Pharmacy; University of Illinois Medical Center at Chicago

Experiential

Introductory & Advanced Pharmacy Practice Experiences (IPPE & APPE)

1996 – 1997,	Medicine/Advanced Medicine Clerkship Preceptor
2012 – 2017	PMPR 387, PMPR 353, PMPR 395 (APPE)
1999 – 2009	Advanced Medicine Critical Care/Cardiology Preceptor PMPR 389, PMPR 664 (1999 – 2004) (APPE)
2000 – 2017	Experiential II Facilitator: PHAR 352 (IPPE)
2000 – 2017	Experiential III Facilitator: PHAR 353 (IPPE)
2000 – 2017	Experiential IV Facilitator: PHAR 354 (IPPE)
2007 – 2017	Experiential I Facilitator: PHAR 342 (IPPE)
2008 – 2017	Medicine Clerkship Preceptor: PHAR 374 (APPE)
2008 – 2017	Experiential V Preceptor: PHAR 357 (IPPE)
2017 – present	Medicine/Advanced Medicine Clerkship Co-Preceptor: PMPR 387, PHAR 374
2018 – present	PHAR 515: Introductory Pharmacy Practice Experience Co-Preceptor

Residency Preceptor (Critical Care/Cardiology/Cardiothoracic Surgery)

1999 – present	PGY1 Pharmacy Practice Residency Preceptor (required, electives)
2000 – present	PGY2 Critical Care Residency Preceptor (required)
2007 – 2017	PGY2 Emergency Medicine Residency Preceptor (elective)
2007 – 2017	PGY2 Organ Transplant Residency Preceptor (elective)
2008 – present	PGY2 Cardiology Residency Preceptor (required, electives)

Visiting Scholars Preceptor

1999	Kyoshi Mihara (Japan)
2000	Margaret Lin (Taiwan), Emma Boxall (England), Wen-Ling Fu (Taiwan)
2001	M. S. Ganachari (India)
2003	Cheryl Kmet (Canada)
2006	Christine Teng (Singapore)
2009	Lilly Tung (Taiwan), Claire Hsin (Taiwan)
2011	Hou Meng Chong (Singapore)
2012	Ryuichi Ogawa (Japan)
2013	Susanna Bordignon (Italy)
2018	Wipharak Bunmark (Thailand)

Didactic

University of Illinois at Chicago College of Pharmacy

1997 – 1998	Acute Medical Emergencies I: PMPR 366
1998	Ambulatory Care Elective: PMPR 371
1998 – 2000	Careers in Pharmacy: PMPR 375
1998 – 2004	Physical Assessment: PHAR 656
1999 – 2001	Principles of Drug Action and Therapeutics V: PHAR 405
1999 – 2000	Pathophysiology: PHYB 301
2000 – 2008	Critical Care I: PMPR 430
2001 – 2003	Pharmacotherapeutics 651: PHAR 651
2001 – 2016	Principles of Drug Action and Therapeutics II: PHAR 402
2003 – 2007	Experiential IV: PHAR 354 (formerly part of PHAR 353)
2003 – 2008	Applied Pharmacokinetics: PMPR 440 (formerly PMPR 385/340) (Course Coordinator/Course Developer)

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae

2004 – 2005 Undergraduate Research in Pharmacy Practice: PMPR 380
Topic: Development and Verification of a Modern Dosing Nomogram for Digoxin (Student: Melissa Fitch)

2005 – 2016 Basic Pharmacokinetics: PHAR 400

2005 – 2006 Special Projects in Pharmacy Practice: PMPR 390
Topic: Development and Verification of a Modern Dosing Nomogram for Digoxin (Student: Melissa Fitch)

2006 Special Projects in Pharmacy Practice: PMPR 390
Topic: Medication Use Evaluation of IV Heparin Dosing in Hospitalized

2007 Undergraduate Research in Pharmacy Practice: PMPR 380
Topic: Medication Use Evaluation of IV Heparin Dosing in Hospitalized Patients (Student: Harn Shiue)
Patients (Student: Harn Shiue)

2007 – 2011 Seminar in Pharmacy Research: PMPR 355

2009 – 2010 Professional Development Seminar III: BPS/PMAD 383

2010 – 2011 Social and Behavioral Pharmacy: PHAR 344

2016 – present Integrated Physiology: PHAR 410

2016 – present Pharmacokinetics: PHAR 435

2017 – present Principles of Drug Action and Therapeutics V: PHAR 505

2018 – present College of Pharmacy Colloquium: BPS 425

2019 – present Principles of Drug Action and Therapeutics X: PHAR 510

University of Illinois at Chicago College of Medicine

2013 Medical Pharmacology: PRCL 628

University of Illinois at Chicago Honors College

2013 Honors Seminar Course: HON 201 (undergraduates in the Honors College)

OTHER PROFESSIONAL ACTIVITIES

Abstract Reviewer

2017 American College of Cardiology

Grant Reviewer

2015 California Northstate University College of Pharmacy Seed Grant

2015 Heart Failure Society of America (HFSA) Clinical Research Grants

2016 Heart Failure Society of American (HFSA)/Emergency Medicine Foundation (EMF) Research Grants

2016 Heart Failure Society of America (HFSA) Research Fellowship Grants (St. Jude Medical Research)

2016 American College of Clinical Pharmacy (ACCP) Research Institute Futures Grants

2017 Heart Failure Society of America (HFSA) Mini Nursing Research Grants

Promotion and Tenure External Reviewer

2009 University of Southern California Associate Professor of Clinical Pharmacy promotion candidate

2010 Western University of Health Sciences Associate Professor of Clinical Pharmacy promotion candidate

2011, 2012 Purdue University Clinical Associate Professor of Pharmacy Practice promotion candidates

2012 Wayne State University Associate Professor (Clinical) of Pharmacy Practice promotion candidate

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae

2014	University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Assistant Professor reappointment candidate (midpoint assessment for promotion)
2014	University of Missouri Kansas City Clinical Associate Professor of Pharmacy Practice and Administration promotion candidate
2016	University of Tennessee College of Pharmacy Professor (non-tenured) candidate
2017	University of North Carolina Eshelman School of Pharmacy Clinical Professor candidate
2018	Rosalind Franklin University of Medicine and Science Associate Professor (Clinical Educator track) candidate

Editorial Activities

2014 – 2016	Consulting editor, <i>J Pharm Pract</i> 2016;29(1): Cardiology Pharmacotherapy Special issue
2017 – present	Editorial board member, <i>Journal of the American College of Clinical Pharmacy</i>

Reviewer/Referee

1997 – 2017	<i>Annals of Pharmacotherapy</i>
1997 – 1998	<i>Clinical Therapeutics</i>
1998 – present	<i>Pharmacotherapy</i>
1997 – 1999	University Health-System Consortium Drug Monograph
2000	<i>Expert Opinion on Pharmacotherapy</i>
2000	Medical Education Resources
2002 – 2004	<i>RxPress</i>
2003	Premier Purchasing Partners
2004	<i>KeePosted</i>
2005	<i>The Medical Letter</i>
2005	<i>Archives of Internal Medicine</i>
2006	<i>American Society of Health-System Pharmacists</i>
2008	ProCE
2009	<i>American Journal of Cardiology</i>
2009	<i>Pharmacy Practice</i>
2009 – 2010	Pharmacotherapy Self-Assessment Program (PSAP) VII Urgent Care/Critical Care
2009 – 2010	<i>Current Medical Research and Opinion</i>
2010 – 2016	<i>Journal of Cardiac Failure</i>
2013	<i>Journal of Cardiothoracic Surgery</i>
2013 – 2014	Ambulatory Care Self-Assessment Program (ACSAP) Cardiology Care
2014	<i>Thrombosis Journal</i>
2016	<i>Hospital Pharmacists Letter</i>
2017	<i>Pharmacists Letter</i>
2017 – present	<i>Circulation: Heart Failure</i>
2018 – present	<i>Journal of the American College of Clinical Pharmacy</i>

National Advisory Boards

2001 – 2002	Novation MUE Program Glycoprotein IIb/IIIa Inhibitor Expert Panel
2001	Cerner Corporation Clinical Notification Expert Panel
2003	Alza Pharmaceuticals Advisory Board
2005	Scios, Inc. Regional Pharmacy Advisory Board
2005	Scios, Inc. National Pharmacy Advisory Board
2005	Focus Group on IHN (Novation, University Health Consortium, VHA) Perspectives on the Treatment of Acute Decompensated Heart Failure
2006	Ranexa Advisory Board (CV Therapeutics)
2006	NitroMed Clinical Pharmacy Advisory Board

2007	Natrecor® Advisory Panel (Scios, Inc.)
2008	Multaq® Quality Improvement Advisory Board. (Sanofi-Aventis)
2008	Pharmacy/Integrated Health Network (IHN) Advisory Board for Angiomax® (The Medicines Company)
2009	Merck & Co. U. S. Heart Failure Expert Input Forum
2009	ARCA biopharma, Inc. Gencaro® Advisory Board
2010 – 2011	Medscape Drug Reference Advisor
2010	American Pharmacists Association (Special Report: “Updates in the Management of Chronic Stable Angina”)
2010	Merck & Co. Cardiovascular Outcomes Research Advisory Panel
2011	F. Hoffmann-La Roche Ltd Cardiovascular Advisory Board
2013	Novartis Pharmaceuticals Corp. Hospital Pharmacy Perspectives on Acute Heart Failure Advisory Board
2014	Novartis Pharmaceuticals Corp. Chronic Heart Failure Commercial Advisory Board
2014	Amgen Hospital Pharmacy Cardiovascular Advisory Board
2014	Novartis Pharmaceuticals Corp. Acute Heart Failure Hospital Pharmacy Decision Maker Early Experience Program Advisory Board
2015	Otsuka America Pharmaceutical, Inc. SCORE Tool Advisory Board

National Speaker Bureaus

1998 – 2004	Integrilin® Speaker Bureau (Shering-Plough, Key Pharmaceuticals, Millenium Pharmaceuticals, COR Therapeutics)
2000 – 2002	Cordarone® IV Educator
2000 – 2001	Tikosyn™ Medical Educator (Pfizer, Inc./Current Medical Directions, Inc.)
2000 – 2001	Bristol-Myers-Squibb Speaker Bureau (Pravachol®, Plavix®)
2004 – 2006	University Pharmacotherapy Associates, LLC Acute Decompensated Heart Failure speaker program
2005 – 2007	Natrecor® Speaker Bureau (Scios, Inc.)
2007 – 2010	STRIVE™ Critical Pathways CME/CE Workshop (Bristol-Myers-Squibb, Sanofi Pharmaceuticals, Sanofi-Aventis US, Inc.)
2007 – 2008	University Pharmacotherapy Associates, LLC Acute Coronary Syndrome speaker program

CONSULTING RELATIONSHIPS

2002 – 2004	Abbott Laboratories.
2002 – 2003	Baxter Healthcare Corp.
2006 – 2007	Heyl, Royster, Voelker, & Allen
2006	Rakoczy Molino Mazzochi Siwik LLP.
2012	Clarus Acuity Group, Inc.
2012	Cassiday Schade LLP
2013	Edwards Wildman Palmer LLP

COMMUNITY & PROFESSIONAL SERVICE

Professional Interviews

2000	Interviewed for Cover Story on “The pharmacist’s role on anticoagulation team expanding as anticoagulant usage increases” for <i>Hospital Pharmacist Report</i> . Vecchione A. Anticoagulation: New Therapeutic Challenges: R.Ph.s becoming vital members of health-care team as anticoagulant use increases. <i>Hospital Pharmacist Report</i> 2000;14:31-2.
------	---

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae

- 2000 Television interview on WBBM-TV (CBS) Channel 2 News at 10 regarding new FDA warning on the serious cardiovascular complications associated with Propulsid (cisapride). "On Call with Dr. Michael Breen, MD". Segment aired January 24, 2000.
- 2003 Interviewed for story appearing in the University of Illinois at Chicago donor recognition newsletter. McKeough K. "Pharmacy Fraternities Endow Scholarship Funds: Gifts from Kappa Psi, Phi Delta Chi Alumni Help Foster Student Leadership". *Investing in UIC*; December, 2003.
- 2003 Interviewed for story appearing in *Pharmacy Practice News*. Hurley D. "PDAs Can Be Pharmacist's Best Friend When It Comes to Proper Antibiotic Prescribing". *Pharmacy Practice News* 2004;31. [November, 2003](#).
- 2007 Interviewed for story entitled "Multiple changes spawn new UA/NSTEMI guidelines" appearing in *Drug Topics*; [September 17, 2007](#).
- 2007 Interviewed for story on "5 drug interactions to keep on your radar" appearing in the family health issue of the Chicago Tribune's Sunday magazine. Chen D. "Take Five". *Chicago Tribune Magazine*; [March 4, 2007](#).
- 2010 Interviewed for story entitled "New antiplatelet agents enter a market dominated by clopidogrel: Prasugrel, ticagrelor, and more to come." appearing in *Pharmacy Today*. October, 2010.
<http://apha.imirus.com/Mpowered/imirus.jsp?volume=pt16&issue=10&page=38>
- 2012 Interviewed for story entitled "Is fibrate-statin ban a bad idea?" appearing in *Pharmacy Practice News*. [December, 2012;39](#).
- 2013 Interviewed for story entitled "Fibrate-statin changes mandate new safety protocols?" appearing in *Pharmacy Practice News*. [January, 2013;40](#).
- 2014 Interviewed for story entitled "Pharmacists part of interventions in readmission programs for patients with heart failure, AHRQ says." appearing in *Pharmacy Today* 2014;20(7).
- 2017 Interviewed for story entitled "CardioMEMS PA-pressure sensor: prowess, cautions in HF management" appearing on [Medscape. September 19, 2017](#).
- 2018 Interviewed for story entitled "Despite increased mortality, DOAC safety data offer reassurance" appearing in [Pharmacy Today 2018;24\(9\):4](#).

American Pharmacists Association

- 2018 Panelist, American Pharmacists Association (APhA) University of Illinois at Chicago (UIC) Chapter Heart Operation

American Heart Association

- 2004 – 2012 Participant, American Heart Association Heart Walk c/o University of Illinois Medical Center at Chicago. 2004 – 2012.
- 2010 Team Captain (Inpatient Pharmacy), American Heart Association Heart Walk c/o University of Illinois Medical Center at Chicago. 2010.

St. Alphonsus/St. Patrick School

- 2014 – 2015 Assistant Coach, Boys Basketball. Lemont Park District Lepercauns. Lemont, IL.
- 2015 – 2017 Assistant Coach, Boys Basketball, 5th-6th grades. St. Alphonsus/St. Patrick School. Lemont, IL.
- 2016 – 2018 Member, St. Alphonsus/St. Patrick School Celtic Fund Marketing Committee. Lemont, IL.

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHSA, FACC
Curriculum Vitae

- | | |
|----------------|--|
| 2017 | Member, St. Alphonsus/St. Patrick School Advisory Task Force Strategic Planning Subcommittee |
| 2017 – 2018 | Head Coach, Boys Basketball, 6 th /7 th grade. St. Alphonsus/St. Patrick School. Lemont, IL. |
| 2018 – 2019 | Head Coach, Boys Basketball, 5 th /6 th grade. St. Alphonsus/St. Patrick School. Lemont, IL |
| 2018 – present | Basketball Coordinator, St. Alphonsus/St. Patrick School Athletics Board. Lemont, IL. |
| 2018 – present | Head Coach, Boys Basketball, 7 th /8 th grade. St. Alphonsus/St. Patrick School. Lemont, IL |

Miscellaneous

- | | |
|------|---|
| 2004 | Recognition by American Airlines for participating in the emergency medical care of a passenger in need of Advanced Cardiac Life Support during a flight from Chicago, Illinois to Reno, Nevada. September, 2004. |
| 2004 | Member, South Loop Dog Park Action Co-op (Dog P.A.C.). Involved in fundraising activities for the construction of a dog park at the south end of Grant Park in Chicago. 2004. |